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CHAPTER-I 
INTRODUCTION 
The oral route of drug administration is the most common and preferred method 
of delivery due to convenience and ease of ingestion. From a patient’s perspective, 
swallowing a dosage form is a comfortable and a familiar means of taking medication. 
As a result, patient compliance and hence drug treatment is typically more effective 
with orally administered medications as compared with other routes of administration, 
for example,parenteral. Although the oral route of administration is preferred, for many 
drugs it can be a problematic and inefficient mode of delivery for a number of reasons. 
Limited drug absorption resulting in poor bioavailability is paramount amongst the 
potential problems that can be encountered when delivering an active agent via the oral 
route. Drug absorption from the gastrointestinal tract (GIT) can be limited by a variety 
of factors with the most significant contributors being poor aqueous solubility and/or 
poor membrane permeability of the drug molecule. When delivering an active agent 
orally, it must first dissolve in gastric and/or intestinal fluids before it can then 
permeate the membranes of the GI tract to reach systemic circulation. Therefore, a drug 
with poor aqueous solubility will typically exhibit dissolution rate limited absorption, 
and a drug with poor membrane permeability will typically exhibit permeation rate 
limited absorption .Hence, two areas of pharmaceutical research that focus on 
improving the oral bioavailability of active agents include: (i) enhancing solubility and 
dissolution rate of poorly water-soluble drugs and (ii) enhancing permeability of poorly 
permeable drug. (Lewis S et al., 2009) 
The poor solubility and low dissolution rate of poorly water soluble drugs in the 
aqueous gastro-intestinal fluids often cause insufficient bioavailability rather than the 
limited permeation through the epithelia and the formulation of poorly soluble drugs for 
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oral delivery now presents one of the major challenges to formulation scientists in the 
industries. A review of new monograph (1992-1995) in European pharmacopoeia 
shows that more than 40% of the drug substances have aqueous solubility below 
1mg/ml and the 32% have an aqueous solubility below 0.1mg/ml.(Aruna Rawat et 
al.,2011). 
Most of the newly discovered chemical entities, in spite of high therapeutic 
activity, have low aqueous solubility and poor bioavailability, leading to poor 
absorption in the gastrointestinal tracts. For absorption of the drug from the 
gastrointestinal tracts (GIT), the drug should be present in solution state in GI fluid, 
which forms a critical requirement for absorption of poorly water-soluble drugs. (Shilpi 
Sinha et al., 2010)  
 The solubility of a drug is a key determinant of its oral bioavailability and 
permeability. There have always been certain drugs for which solubility has presented a 
challenge to the development of a suitable formulation for oral administration. 
Examples such as griseofulvin, digoxin, phenytoin, sulphathiazole and chloramphenicol 
etc., With the recent advent of high throughput screening of potential therapeutic 
agents, the number of poorly soluble drug candidates has risen sharply and the 
formulation of poorly soluble compounds for oral delivery now presents one of the 
most frequent and greatest challenges to formulation scientists in the pharmaceutical 
industry. (Anshu Sharma et al., 2011) 
Solubility 
The term ‘solubility’ is defined as maximum amount of solute that can be 
dissolved in a given amount of solvent. Quantitatively it is defined as the concentration 
of the solute in a saturated solution at a certain temperature. In qualitative terms, 
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solubility may be defined as the spontaneous interaction of two or more substances to 
form a homogenous molecular dispersion. 
Prediction of solubility: 
Probably the most sought-after information about solutions in formulation 
problems is 'what is the best?' or 'what is the worst?' solvent for a given solute. 
Theoretical prediction of precise solubilities is an involved and occasionally 
unsuccessful operation, but from knowledge of the structure and properties of solute 
and solvent an educated guess can be made. This is best expressed in subjective terms, 
such as 'very soluble' or 'sparingly soluble'. Often (particularly in pre- or early 
formulation) this is all the information that the formulator requires. The 
interrelationships between such terms and approximate solubilities are shown in Table. 
(Aulton M.E et al .,2002) 
 
Description Approximate weight of solvent (g) 
necessary to dissolve 1 g of solute 
Very soluble < 1 
Freely soluble Between 1 and 10 
Soluble Between 10 and 30 
Sparingly soluble Between 30 and 100 
Slightly soluble Between 100 and 1000 
Very slightly soluble Between 1000 and 10 000 
Practically insoluble Above 10 000 
 
PROCESS OF SOLUBILISATION:- 
The process of solubilisation involves the breaking of inter-ionic or 
intermolecular bonds in the solute, the separation of the molecules of the solvent to 
provide space in the solvent for the solute, interaction between the solvent and the 
solute molecule or ion (Harinath N.More et al., 2007). 
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Noyes-Whitney equation (1) illustrates how the dissolution rate of even very poorly 
soluble compounds might be improved to minimize the limitations to oral 
bioavailability:  
                                 dC/dt *h = AD. (Cs - C) ----------------- (1) 
Where, 
 dC/dt is the rate of dissolution, 
 A is the surface area available for dissolution, 
 D is the diffusion coefficient of the compound,  
Cs is the solubility of the compound in the dissolution medium, 
 C is the concentration of drug in the medium at time t, 
 h is the thickness of the diffusion boundary layer adjacent to the surface of the 
dissolving compound.  
 
 BCS CLASSIFICATION 
The BCS was first devised in 1995 by Amidon et al. According to the BCS, 
drug substances can be classified as belonging to one of four classes: 
 Class 1: high solubility and high permeability 
 Class 2: low solubility and high permeability 
 Class 3: high solubility and low permeability 
 Class 4: low solubility and low permeability 
Especially for class II substances according to the Biopharmaceutical 
Classification System (BCS), the bioavailability may be enhanced by increasing the 
solubility and dissolution rate of the drug in the gastro-intestinal fluids. Drug release is 
a crucial and limiting step for oral drug bioavailability, particularly for drugs with low 
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So is the solubility of fine particles, 
V is molar volume, 
g is the surface tension of the solid,  
r is the radius of the fine particle.  
Temperature  
Temperature will affect solubility. If the solution process absorbs energy then 
the solubility will be increased as the temperature is increased. If the solution process 
releases energy then the solubility will decrease with increasing temperature. 
Generally, an increase in the temperature of the solution increases the solubility of a 
solid solute. A few solid solutes are less soluble in warm solutions. For all gases, 
solubility decreases as the temperature of the solution increases.  
Pressure 
For gaseous solutes, an increase in pressure increases solubility and a decrease 
in pressure decrease the solubility. For solids and liquid solutes, changes in pressure 
have practically no effect on solubility.  
Nature of the solute and solvent  
While only 1 gram of lead (II) chloride can be dissolved in 100 grams of water 
at room temperature, 200 grams of zinc chloride can be dissolved. The great difference 
in the solubilities of these two substances is the result of differences in their natures.  
Molecular size 
Molecular size will affect the solubility. The larger the molecule or the higher 
its molecular weight the less soluble the substance. Larger molecules are more difficult 
to surround with solvent molecules in order to solvate the substance. In the case of 
organic compounds the amount of carbon branching will increase the solubility since 
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more branching will reduce the size (or volume) of the molecule and make it easier to 
solvate the molecules with solvent.  
Polarity 
Polarity of the solute and solvent molecules will affect the solubility. Generally 
non-polar solute molecules will dissolve in non-polar solvents and polar solute 
molecules will dissolve in polar solvents. The polar solute molecules have a positive 
and a negative end to the molecule. If the solvent molecule is also polar, then positive 
ends of solvent molecules will attract negative ends of solute molecules. This is a type 
of intermolecular force known as dipole-dipole interaction. All molecules also have a 
type of intermolecular force much weaker than the other forces called London 
Dispersion forces where the positive nuclei of the atoms of the solute molecule will 
attract the negative electrons of the atoms of a solvent molecule. This gives the non-
polar solvent a chance to solvate the solute molecules.  
Polymorphs 
A solid has a rigid form and a definite shape. The shape or habit of a crystal of a 
given substance may vary but the angles between the faces are always constant. A 
crystal is made up of atoms, ions, or molecules in a regular geometric arrangement or 
lattice constantly repeated in three dimensions. This repeating pattern is known as the 
unit cell. The capacity for a substance to crystallize in more than one crystalline form 
is polymorphism. It is possible that all crystals can crystallize in different forms or 
polymorphs. If the change from one polymorph to another is reversible, the process is 
called enantiotropic. If the system is monotropic, there is a transition point above the 
melting points of both polymorphs. The two polymorphs cannot be converted from 
one another without undergoing a phase transition. Polymorphs can vary in melting 
point. Since the melting point of the solid is related to solubility, so polymorphs will 
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have different solubilities. Generally the range of solubility differences between 
different polymorphs is only 2-3 folds due to relatively small differences in free 
energy. 
RATE OF SOLUTION: 
The rate of solution is a measure of how fast substances dissolve in solvents.  
FACTORS AFFECTING RATE OF SOLUTION: 
Size of the particles  
When the total surface area of the solute particles is increased, the solute 
dissolves more rapidly because the action takes place only at the surface of each 
particle. Breaking a solute into smaller pieces increases its surface area and hence its 
rate of solution.  
Temperature 
For liquids and solid solutes, increasing the temperature not only increases the 
amount of solute that will dissolve but also increases the rate at which the solute will 
dissolve. For the gases, reverse is true.  
Amount of solute already dissolved  
When there is little solute already in solution, dissolution takes place relatively 
rapidly. As the solution approaches the point where no solute can be dissolved, 
dissolution takes place more slowly.  
Stirring  
With liquid and solid solutes, stirring brings fresh portions of the solvent in 
contact with the solute, thereby increasing the rate of solution.  
TECHNIQUES OF SOLUBILITY ENHANCEMENT 
There are various techniques available to improve the solubility of poorly 
soluble drugs. Some of the approaches to improve the solubility are:  
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I. Physical Modifications 
A. Particle size reduction  
• Micronization  
• Nanosuspension  
B. Modification of the crystal habit  
• Polymorphs  
• Pseudopolymorphs  
C. Drug dispersion in carriers  
• Eutectic mixtures  
• Solid dispersions  
• Solid solutions  
D. Complexation  
• Use of complexing agents  
E. Solubilization by surfactants:  
• Microemulsions  
• Self microemulsifying drug delivery systems.  
II. Chemical Modifications:- 
For organic solutes that are ionizable, changing the pH of the system may be 
simplest and most effective means of increasing aqueous solubility. Under the proper 
conditions, the solubility of an ionizable drug can increase exponentially by adjusting 
the pH of the solution. A drug that can be efficiently solubilized by pH control should 
be either weak acid with a low pKa or a weak base with a high pKa. Similar to the lack 
of effect of heat on the solubility of non-polar substances, there is little effect of pH on 
nonionizable substances. Nonionizable, hydrophobic substances can have improved 
solubility by changing the dielectric constant (a ratio of the capacitance of one material 
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to a reference standard) of the solvent by the use of co-solvents rather than the pH of 
the solvent.  The use of salt forms is a well known technique to enhanced dissolution 
profiles. Salt formation is the most common and effective method of increasing 
solubility and dissolution rates of acidic and basic drugs. An alkaloid base is, 
generally, slightly soluble in water, but if the pH of medium is reduced by addition of 
acid, and the solubility of the base is increased as the pH continues to be reduced. The 
reason for this increase in solubility is that the base is converted to a salt, which is 
relatively soluble in water (e.g. Tribasic calcium phosphate).The solubility of slightly 
soluble acid increased as the pH is increased by addition of alkali, the reason being 
that a salt is formed  e.g. Aspirin, Theophylline, Barbiturates. ( Harinath N.More et 
al.,2007) 
BIOAVAILABILITY ENHANCEMENT THROUGH ENHANCEMENT 
OF DRUG SOLUBILITY OR DISSOLUTION RATE 
There are several ways by which drug solubility or the dissolution rate can be 
enhanced. Some of widely used methods are as follows, 
 Micronization 
 Nanonisation 
 Supercritical fluid recrystallization 
 Spray freezing into liquid(SFL) 
 Evaporative precipitation into aqueous solution (EPAS) 
 Use of surfactants 
 Use of salt forms 
 Use of precipitation Inhibitors 
 Alteration of pH of the Drug Microenvironment 
 Use of Amorphs, Anhydrates, Solvates and Metastable Polymorphs 
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                                                  CHAPTER-II  
                                SOLID DISPERSION – A REVIEW  
Solid dispersion was introduced in the early 1970s, refers to a group of solid 
products consisting of at least two different components, generally a hydrophilic 
matrix and a hydrophobic drug (Aruna Rawat  et al.,2011).                               
 The term solid dispersion refers to a group of solid products consisting of at 
least two different components, generally a hydrophilic matrix and a hydrophobic 
drug. The matrix can be either crystalline or amorphous. The drug can be dispersed 
molecularly, in amorphous particles (clusters) or in crystalline particles (Lewis S et 
al.,2009). 
CLASSIFICATION: 
First generation solid dispersions:  
Description of solid dispersions was given from Sekiguchi and Obi in 1961 
showed that formulation of eutectic mixtures improved the rate of drug release which in 
turn increases the bioavailability of poorly water soluble drugs. Later, Levy and Kaning 
developed solid dispersion. The first systems, containing mannitol as carrier, by 
preparing solid solutions through molecular dispersions instead of using eutectic 
mixtures. They have the disadvantage of forming crystalline solid dispersions, which 
were more thermodynamically stable and did not release the drug as quickly as 
amorphous ones. 
Second generation solid dispersions 
It was noticed in the late sixties that Solid dispersion with drug in the crystalline 
state is not as effective as amorphous because they are thermodynamically stable. 
Therefore, second generations of solid dispersions were introduced having amorphous 
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carriers instead of crystalline. Formerly, the drugs were molecularly dispersed in 
amorphous carriers which are usually polymers in random pattern. 
Third generation solid dispersions 
Third generation of solid dispersions appeared as the dissolution profile could 
be increased by using carriers having surface activity and self-emulsifying 
characteristics. These contain surfactant carriers or a mixture of amorphous polymers 
and a surfactant as carrier.  The third generation solid dispersions stabilize the solid 
dispersions, increase the bioavailability of the poorly soluble drugs and reduce 
recrystallisation of drug. Surfactants have been included to stabilize the formulations, 
thus avoiding drug recrystallization and potentiating their solubility (Aruna Rawat  et 
al.,2011).                            
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ADVANTAGEOUS PROPERTIES OF SOLID DISPERSIONS 
 Particle size 
Molecular dispersions, as solid dispersions, represent the last state on particle 
size reduction and after carrier dissolution the drug is molecularly dispersed in the 
dissolution medium. Solid dispersions apply this principle to drug release by creating a 
mixture of a poorly water soluble drug and highly soluble carriers. 
 Wettability 
A strong contribution to the enhancement of drug solubility is related to the 
drug wettability improvement verified in solid dispersions. It was observed that even 
carriers without any surface activity, such as urea improved drug wettability. Carriers 
with surface activity such as cholic acid and bile salts when used can significantly 
increase the wettability property of drug. Moreover, carriers can influence the drug 
dissolution profile by direct dissolution or co-solvent effects. 
 Porosity 
Particles in solid dispersions have been found to have a higher degree of 
porosity. The increase in porosity also depends on the carrier properties; for instance, 
solid dispersions containing linear polymers produce larger and more porous particles 
than those containing reticular polymers and therefore, result in a higher dissolution 
rate. The increased porosity of solid dispersion particles also hastens the drug release 
profile. 
 Amorphous state 
Poorly water soluble crystalline drugs, when in the amorphous state tend to have 
higher solubility. The enhancement of drug release can usually be achieved using the 
drug in its amorphous state, because no energy is required to break up the crystal 
lattice during the dissolution process. In solid dispersions, drugs are Presented as 
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PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION:  
The pharmaceutical applications of solid dispersions technique are numerous. 
They may be employed-  
1. To enhance the absorption of drug;  
2. To obtain a homogeneous distribution of a small amount of drug in solid state;            
3.       To stabilize unstable drugs and protect against decomposition by processes such  
          as hydrolysis, oxidation, racemization, photo oxidation etc.;  
  4.        To dispense liquid or gaseous compounds;  
  5.        To formulate a fast release priming dose in a sustained release dosage form;  
  6.        To formulate sustained release preparation of soluble drugs by dispersing the 
              drug in poorly soluble or insoluble carrier;  
  7.        To reduce side effects-(a) the binding ability of drugs for example to the    
             erythrocyte membrane is decreased by making its inclusion complex, (b) the    
             damage to the stomach mucous membranes by certain non-steroidal anti- 
             inflammatory drugs can be reduced by administration as an inclusion  
             compound;  
  8.         To mask unpleasant taste and smell. The very unpleasant taste of anti- 
               depressant famoxetine hindered the development of oral liquid formulations.  
               The bitter taste was greatly suppressed when the solid complex of famoxetine  
               was formulated as aqueous suspension;  
  9.          To convert liquid compounds into formulations. Liquid drugs can be    
               manufactured as solid drug formulations such as powders, capsules or tablets  
               e.g., unsaturated fatty acids, essential oils, nitroglycerin, benzaldehyde,  
               prostaglandin, clofibrate etc. (Anshu Sharma et al.,2011) 
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DISADVANTAGES: 
The limitations of this technology have been a drawback for the 
commercialization of solid dispersions, the limitations include 
1. Laborious and expensive methods of preparation, 
2. Reproducibility of physicochemical characteristics, 
3. Difficulty in incorporating into formulation of dosage forms, 
4. Scale-up of manufacturing process  
5. Stability of the drug and vehicle. 
CARRIERS: 
The properties of the carrier have the major influence on the dissolution profile 
of the dispersed drug. A carrier should meet the following criteria to meet to be suit for 
increasing the dissolution rate of drug. 
Selection of a carrier: 
A carrier should meet the following criteria to be suitable for increasing the 
dissolution rate of a drug. 
1. Freely water-soluble with intrinsic rapid dissolution properties. 
2. Non-toxic and pharmacologically inert. 
3. Heat stable with a low melting point for the melt method. 
4. Soluble in a variety of solvents and pass through a vitreous state upon solvent  
      evaporation for the solvent method. 
5. Able to preferably increase the aqueous solubility of the drug and 
6. Chemically compatible with the drug and not form a strongly bonded complex with  
     the drug. 
First generation carriers: 
Example: Crystalline carriers: Urea, Sugars and Organic acids.  
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Second generation carriers: 
Example: Fully synthetic polymers include povidone (PVP), 
polyethyleneglycols (PEG) and polymethacrylates. Natural product based polymers 
are mainly composed by cellulose derivatives, such as hydroxypropylmethylcellulose 
(HPMC), ethylcellulose or hydroxypropylcellulose or starch derivates, like 
cyclodextrins. 
Third generation carriers: 
Example: Surface active self emulsifying carriers: Poloxamer 408, Tween 80, 
and Gelucire 44/14. 
CARRIERS FOR SOLID DISPERSIONS 
Sl. No.  Chemical Class  Examples  
1  Acids  Citric acid, Tartaric acid, Succinic acid  
2  Sugars  Dextrose, Sorbitol, Sucrose, Maltose, 
Galactose, Xylitol  
3  Polymeric Materials  Polyvinylpyrrolidone, PEG-4000, PEG-
6000,  
Carboxymethyl cellulose, Hydroxypropyl 
cellulose,  
Guar gum, Xanthan gum, Sodium 
alginate, Methyl  
cellulose, HPMC, Dextrin, Cyclodextrins,  
Galactomannan  
4  Surfactants  Polyoxyethylene stearate, Poloxamer,  
Deoxycholic acid, Tweens and Spans,  
Gelucire 44/14, Vitamine E TPGS NF  
5  Miscellaneous  Pentaerythritol, Urea, Urethane,  
Hydroxyalkyl xanthines  
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METHOD OF PREPARATION:  
Fusion method  
The fusion method is sometimes referred to as the melt method, which is correct 
only when the starting materials are crystalline. Sekiguchi and obi were the first to use 
a melting method consisting of melting the drug within the carrier followed by cooling 
and pulverization of the obtained product. A common adaptation to the melting phase 
consists of suspending the active drug in a previously melted carrier, instead of using 
both drug and carrier in the melted state, therefore reducing, the process temperature. 
To cool and solidify the melted mixture, several processes such as ice bath agitation, 
stainless steel thin layer spreading followed by a cold draught, solidification on petri 
dishes at room temperature, inside a dessicator, spreading on plates placed over dry 
ice, immersion in liquid nitrogen or stored in a dessicator were used. After cooling, the 
mixture must be pulverized regarding its handling (Anshu Sharma et al.,2011). 
Freeze Drying Method:  
Drug formulations were processed using ultra-rapid freezing technology. 
Hydrophilic excipient was dissolved in methanol. Drug, which is poorly water soluble, 
was added to this separately and dissolved. The resulting ternary system of organic 
solvent, hydrophilic carrier, and drug was freeze-dried by filling glass vials with the 
solutions and positioning the vials in a lyophilizer. During operation, the freeze-drier 
was maintained at -45 °C and a compressional pressure of 0.5 Torr. After complete 
drying, the vials were taken out, and the dried products were scraped from the vials. 
The formulations were powdered and packaged in glass vials. ( Anjan K. Mahapatra  et 
al.,2011) 
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Solvent Evaporation Method 
Tachibana and Nakumara were the first to dissolve both the drug and the carrier 
in a common solvent and then evaporate the solvent under vacuum to produce a solid 
solution. This enabled them to produce a solid solution of the highly lipophilic β-
carotene in the highly water soluble carrier polyvinylpyrrolidone. An important 
prerequisite for the manufacture of a solid dispersion using the solvent method is that 
both the drug and the carrier are sufficiently soluble in the solvent. The solvent can be 
removed by various methods like by spray-drying or by freeze-drying. Temperatures 
used for solvent evaporation generally lie in the range 23-65
0
 C (Harinath.N More et 
al.,2007). 
Melting –solvent method 
A drug is first dissolved in a suitable liquid solvent and then this solution is 
incorporated into the melt of polyethylene glycol, obtainable below 70 
0 
C without 
removing the liquid solvent. The selected solvent or dissolved drug may not be 
miscible with the melt of the polyethylene glycol. Also polymorphic form of the drug 
precipitated in the solid dispersion may get affected by the liquid solvent used 
(Harinath.N More et al.,2007). 
Kneading method 
The physical mixture of drug and carrier were triturated using small quantity of 
organic solvent and water mixture, usually alcohol and water (1:1 v/v). The slurry is 
kneaded for 60 minutes and dried under vaccum for 24 hours. The dried mass is 
pulverized and sieved through sieve No 60 and stored in a desiccators (Ganesh 
chaulang et al., 2009). 
           The advantages of this method are low temperature requirement for solid 
dispersion preparation and usage of organic solvent is less. 
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Hot melt extrusion  
Hot-stage extrusion (HME) consists of the extrusion, at high rotational speed, of 
the drug and carrier, previously mixed, at melting temperature for a small period of 
time. The resulting product is then collected after cooling at room temperature and 
milled. A reduction in processing temperature can be achieved by the association of 
hot-stage extrusion with the use of carbon dioxide as a plasticizer, which broadens the 
application of hot-stage extrusion to thermally labile compounds. Solid dispersions of 
Para-amino salicylic acid / Ethylcellulose, Itraconazole / PVP and Itraconazole / 
Ethylcellulose were successfully prepared by this technique (Anshu Sharma et 
al.,2011). 
Spray drying technique 
In this technique is one of the most commonly used solvent evaporation 
procedure in the production of solid dispersions. It consists of dissolving or 
suspending the carriers, and then spraying it into a stream of heated air flow to remove 
the solvent (Narasaiah V.L et al., 2011). 
Supercritical fluid methods 
Supercritical fluid methods are mostly applied with carbon dioxide (CO2), 
which is used as either a solvent for drug and matrix or as an anti-solvent. When 
supercritical CO2 is used as solvent, matrix and drug are dissolved and sprayed 
through a nozzle, into an expansion vessel with lower pressure and particles are 
immediately formed. The adiabatic expansion of the mixture results in rapid cooling. 
This technique does not require the use of organic solvents and since CO2 is 
considered environmentally friendly, this technique is referred to as ‘solvent free’. The 
technique is known as Rapid Expansion of Supercritical Solution (RESS). However, 
the application of this technique is very limited, because the solubility in CO2 of most 
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(a) Inability to scale bench top formulations to manufacturing- sized batches,  
(b) Difficulty to control physicochemical properties, 
(c) Difficulty in delivering solid dispersion formulations as tablet or capsule  
     dosage forms            
(d) Physical and chemical instability of the drug and/or the formulation itself          
      (Purachikodi A et al.,2010) 
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Swain S.K. et al., 2011.  Design and evaluation of sustained release solid 
dispersion of Verapamil hydrochloride, with HPMCK4M, Eudragit RSPO by 
solvent evaporation method. Investigation of the properties of the prepared solid 
dispersions was performed using release studies and FT-IR. The above research it 
may be concluded that HPMC K4M acts as a better release retardant for the model 
drug.  
Kalyanwat R et al., 2011.   Study of enhancement of dissolution rate of 
carbamazepine by solid dispersion technique. The solid dispersion of 
carbamazepine was prepared by modified solvent evaporation method. Two types 
of superdisintegrants croscarmellose sodium & sodium starch glycolate were 
incorporated. Then prepared different batches of solid dispersion were evaluated by 
drug content, solubility & dissolution study. Thus dissolution rate of carbamazepine 
was found to be increasing with superdisintegrant addition.  
 Raja Rajeswari. K et al.,2011. Development, characterization and solubility study 
of solid dispersion of valsartan. In the present study an attempt was made to 
improve the solubility and dissolution rate using solid dispersion of a poorly water 
soluble drug valsartan by using Soluplus as carrier material to enhance the 
solubility as well as dissolution rate. 5 different formulation were prepared using 
hot melt extrusion technique in different ratios – 1:1, 1:3,1;5,1:7,1:9. The 
formulations were further characterized by FT-IR,DSC&SEM analysis. 
Formulation containing drug: polymer of 1:9 showed the best release with 
cumulative % drug release of 100 %. 
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 Bobe K.R. et al 2011. Formulation and evaluation of solid dispersion of 
Atorvastatin with carriers like PEG4000, PVP K30, and Mannitol by solvent 
evaporation and hot melt method. These solid dispersions were analysed for the 
solubility and invitro dissolution profile, solid dispersion of drug with PEG 4000 
had shown enhanced solubility with improved dissolution rate .Further FT-IR, DSC 
& SEM studies were carried out. Solid dispersion prepared with PEG 6000 shows 
the presence of amorphous form confirmed by the characterization study.  
Bindu Madhavi.B et al., 2011 Dissolution enhancement of  Efavirenz by solid 
dispersion and PEGlylation techniques. Solid dispersions were prepared by solvent 
evaporation and physical mixture method by using PEG. PEGlylated product was 
also prepared. The prepared products were evaluated for various parameters such as 
polymer interaction, saturation solubility study and drug release studies .There is an 
improvement in the dissolution from 10% to 70 % with solid dispersion techniques.  
 Aswini kumar.G et al., 2011 Enhancement of solubility and dissolution rate of 
Irbesartan by solid dispersion techniques employing various superdisintegrants such 
as SSG, CP , CCS, MCC. . Solid dispersions were prepared by solvent evaporation 
and physical mixture method various ratios of drug and carriers were used in the 
preparation in the ratio of 1:1,1:2, and 1:4. Phase solubility studies of pure drug and 
solid dispersion was performed. It was found that solubility of irbesartan was 
increased. The order of increase in dissolution rate with various superdisintegrants 
CP>SSG>CCS>MMC with irbesartan .FT-IR studies revealed that these was no 
chemical interaction between drug and carrier when formed as solid dispersion. 
Vidyadhara. S et al., 2011.  Formulation and evaluation of Glimepride solid 
dispersions and their tablet formulation for enhanced bioavailability. The solid 
dispersions of Glimeoride with SSG at different ratios were prepared by physical 
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mixing, solvent evaporation and kneading methods. Among the 3methods employed 
solvent evaporation and kneading methods were found to be suitable for improving 
the dissolution rate of Glimepride.  
 Chaudhari P.D et al.,2011      Solubility enhancement of Etoricoxib by solid 
dispersion prepared by spray drying technique. The present study was aimed to 
enhance the solubility and dissolution rate of Etoricoxib by solid dispersions with 
poloxamer 407 and gelucire 50/13 prepared by spray drying technique. It can be 
concluded based on the observations of the study that the amorphous form of 
Etoricocib showed improved biopharmaceutical properties.  
 Sandeep kumar et al.,2011.  Effect of non ionic surfactant on the solubility and 
dissolution of simvastatin.  In the present study an attempt has been made to 
improve the solubility and dissolution of poorly water soluble drug   simvastatin 
using  poloxamer 188 as carrier. The kneading technique was used to prepare SD in 
different ratios In conclusion, solubility and dissolution enhancement of simvastatin 
was improved by preparing its solid dispersion with poloxamer 188.  
 Anjan K. Mahapatra et al.,2011. Dissolution Enhancement and Physicochemical 
Characterization of Valsartan in Solid Dispersions with β-CD, HP β-CD, and PVP 
K-30. Solid dispersions and physical mixtures of valsartan were prepared to 
increase its solubility characteristics. The drug formulations were characterized in 
the solid state by FTIR and DSC. By these physical determinations, drug–polymer 
interactions were found. Both the solubility and the dissolution rate of the drug in 
these formulations were increased. The FTIR spectroscopic studies show the 
stability of valsartan and the absence of well-defined drug–polymer interaction. 
Compared with β-CD, HP β-CD showed better enhancement of dissolution rate; 
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compared with HP β-CD, PVP K-30 showed better solubility and dissolution 
enhancement.  
 Akiladevi.D et al., 2011. Preparation And Evaluation Of Paracetamol By Solid 
Dispersion Technique. The solid dispersion of paracetamol by physical triturating 
method, and fusion method were prepared using 1:1, 1:4 and 1:5 ratios of drug and 
polymers (PEG 4000, PEG 6000 and urea) . The solid dispersion was characterized 
for physical appearance, solubility, IR, and in vitro dissolution studies. FTIR study 
revealed that drug was stable in SDs. Solubility of paracetamol from SDs increased 
in distilled water. The drug content was found to be high and uniformly distributed 
in the all formulation. The in vitro dissolution studies were carried using USP type 
XXVII (paddle) type dissolution apparatus. The prepared dispersion showed 
marked increase in the dissolution rate of paracetamol than that of pure drug.  
Dehghan et al.,2010.  Comparative dissolution study of Glipizide by solid 
dispersion technique using carriers like PEG 6000, Mannitol by fusion method & 
PVP K30 by solvent evaporation method. PEG 6000 shows greater solubility and 
dissolution enhancing capacity than mannitol .  
Anshu Sharma et al.,2010.  Preparation and characterization of solid dispersion of 
Valsartan with poloxamer 188 by melting method. The solubility of drug increased 
with increasing polymer concentration. The solid dispersion technique with 
poloxamer 188 as a carrier provides a promising way to enhance the solubility and 
dissolution rate of valsaran.  
Appa Roa.B et al., 2010. Formulation and evaluation of Aceclofenac solid 
dispersions for dissolution rate enhancement using water soluble carriers like 
lactose, mannitol and urea by solvent evaporation method. In-vitro release profiles 
of all solid dispersions were comparatively evaluated and also studied against pure 
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Aceclofenac. Fast dissolution was exhibited by solid dispersion containing 9:1 ratio 
of drug: lactose.  
Ali  Nokhodchi et al., 2010. Enhance dissolution rate of poorly water soluble drug 
carbamazepine using carrier D-Glucosamine Hcl by solvent evaporation method. D-
Glucosamine Hcl as a potential hydrophilic carrier to improve dissolution rate of 
carbamazepine , from physical mixtures and solid dispersions formulations. 
Different solvents( ethanol,acetone&water)  were used as second variable in the 
preparation of solid dispersions ,physical mixtures of carbamazepine and D-
Glucosamine Hcl were also prepared for comparison. The properties of all solid 
dispersions and physical mixtures were studied using a dissolution test, FT-IR 
,SEM and DSC. These results showed that the presence of glucosamine can 
increase dissolution rate of carbamazepine compared to pure drug.  
Gupta Sachin et al.,2010. Comparative study of solubility enhancement of poorly 
soluble drug by solid dispersion and inclusion complex. Famotidine was used as a 
poorly water soluble drug . The inclusion complex with betacyclodextrin and 
hydroxy propyl betacyclodextrin have been prepared by different ratios and found 
that the kneading method shows the better enhancement of solubility in comparison 
to the solvent evaporation method and physical mixture method. The solid 
dispersion with PEG 6000 &4000 have been prepared by different ratios and found 
that solvent evaporation method shows the better enhancement of solubility in 
comparison to the kneading and physical method. The characterization( FT-IR & 
SEM ) of the complexes shows that the drug shows amorphous form of the 
complex. 
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Amit R. Tapas et al., 2010.  Preparation and characterization of spherically 
agglomerated solid dispersions by quasi emulsion solvent diffusion method using 
carriers like PVP K30, HPßCD and HPMC. The pure drug and its agglomerates 
with different polymers were characterize by DSC, PXRD and SEM. Solid 
dispersions with different polymers exhibited marked increase in solubility, 
dissolution rate and micromeritic  properties compound with pure drug.  
 Shilpi Sinha et al., 2010. Solid dispersion as an approach for bioavailability 
enhancement of poorly water soluble drug Ritonavir. The solid dispersion was 
prepared using Gelucire as carrier in 1:4 ratio by different method and were 
characterized for DSC  PXRD,SEM & FT-IR. Oral bioavailability of 10mg 
Ritonavir in solid dispersion prepared by solvent evaporation method and melting 
method was compared with pure drug after oral administration of solid dispersion 
and pure drug to albino wistar rats of either sex .In vitro dissolution studies was 
performed in 0.1N Hcl and bio relevant media showed enhanced dissolution rate as 
compared to pure drug in both media.  
 Arun Prasad et al., 2010.  Preparation and evaluation of solid dispersion of 
Terbinafine Hcl by melting and solvent evaporation method. Using carriers like 
PEG6000,PVP K30. The prepared solid dispersions were characterized for their 
drug content, thermal studies, FT-IR, DSC, Solubility study & dissolution study. 
From the results, it was clear that solid dispersion formulation showed improved 
dissolution rate than pure drug & physical mixture.  
 Prasanthi N.L. et al.,2010.  Studies on dissolution enhancement of poorly water 
soluble drug  ( Lacidipine ) with water soluble carriers like PEG6000, 4000, 
Hydroxy Ethyl Cellulose & Dextrin. The solid dispersions were prepared by solvent 
evaporation method. Evaluation of the dispersion was performed using  dissolution 
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studies, DSC, FT-IR, & PXRD. The result obtained showed that the rate of 
dissolution of Lacidipine was considerably improved when formulated in solid 
dispersions as compare to pure drug.  
 Patel B et al., 2010.   Improvement of solubility of cinnarizine by using solid 
dispersion technique. In the present work solid dispersion of cinnarizine were 
prepared with a PEG 4000 & PVP K30 by using solvent evaporation & fusion 
method in the 1:1, 1:2, 1:3 ratio of drug and carrier respectively. Solid dispersion 
of cinnarizine was evaluated for drug content, FT-IR and in vitro release study. The 
solid dispersion with PEG & PVP exhibited enhanced dissolution rate of 
cinnarizine. IR Spectra revealed no chemical incompatibility between drug & 
carrier. 
 Kothawade S.N et al 2010. Formulation and characterization of Telmisartan solid 
dispersions. solid dispersions were prepared using PVP , PEG 1500 & 4000 to 
increase aqueous solubility . Telmisartan solid dispersions were prepared in 1:1, 1:2 & 
1:4 ratio of the drug to polymer ratio using solvent evaporation method. The 
formulations were characterized for solubility parameters, drug content studies, drug 
release studies and drug – polymer interaction by using FT-IR spectrum. Formulation 
containing 1:2 ratio of drug: PEG4000 showed the best release as compared to pure 
drug. The interaction studies showed no interaction between drug and polymer.  
Siva Ramakrishna G et al.,2010.  Enhanced Dissolution Rate Of Ibuprofen By Solid 
dispersion method.  In this study it was shown that the rate of dissolution of poorly 
soluble drug of ibuprofen was increased by the dispersion of solid dispersions by 
solvent evaporation and melt method. . In solvent evaporation method the drug was 
taken with mannitol in the proportions of (1:1, 1:2and 1:3).In solvent evaporation 
method the rate of dissolution of Ibuprofen was increased with the proportion of (1:3) 
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when compared to the other formulations. In melt dispersion method the rate of 
dissolution of Ibuprofen was increased with the proportion of 1:3) when compared to 
the other formulations. A number of poorly soluble drugs have been shown to improve 
their dissolution characteristics, when converted to  solid dispersion.  
Deshmukh D.B. et al., 2010. Dissolution Enhancement of Poorly Water Soluble 
Diacerein by Solid Dispersion technique using PVP K-30 and HPMC E4 as carriers. 
Four different formulations were prepared by solvent evaporation method with varying 
drug: carrier ratios viz.1:1, 1:2 1:3 and 1:4 and the corresponding physical mixtures 
were also prepared. The formulations were characterized for solubility parameters, 
drug release studies and drug-polymer interactions by using phase solubility studies, 
DSC, XRD analysis, FTIR spectrum. All the formulations showed marked 
improvement in the solubility behavior and improved drug release. . The interaction 
studies showed no interaction between the drug and the carrier.  
 Tejas Patel et al.,2010.   Enhancement of dissolution of Fenofibrate by Solid 
dispersion Technique.   Solid dispersions of Fenofibrate were prepared using PEG 
6000, Poloxamer 407 and a mixture of PEG 6000 and Poloxamer 407(1:1 mixture). 
The effect of melt and solvent methods of preparation of solid dispersion on 
dissolution behavior was also investigated. Dissolution studies indicated a significant 
increase in dissolution of Fenofibrate when dispersed in PEG6000 and Poloxamer 407.  
Venkates  kumar K et al.,2009.  Preparation and invitro characterization of valsartan 
solid dispersions using  skimmed milk powder by dispersion method. Four different 
formulations were prepared with varying drug: lactose viz 1:1,1:2,1:5 and 1:9 and the 
corresponding physical mixtures were also prepared. The formulations were 
characterized for solubility parameters, drug release studies and drug – polymer 
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interaction. All the formulations showed marked improvement in the solubility 
behavior and improved drug release.  
 Kshirsagar S. J et al., 2009.  Dissolution improvement of the poorly water soluble 
drug using dry emulsion and solid dispersion method. The solid dispersions were 
prepared by solvent evaporation method using HPMCE5LV as water soluble carrier & 
lactose improve flow properties of solid dispersion. In vitro drug release of solid 
dispersion was studies by USP Type II   ( Paddle) dissolution apparatus. Probable 
mechanisms of improved solubility were characterized by DSC, PXRD and SEM of 
the drug, Physical mixtures & solid dispersions.  
 Ganesh chanlang et al., 2009. Formulation and evaluation of solid dispersion of 
Furosemide in sodium starch glycolate by kneading method. Solid dispersion of 
furosemide in sodium starch glycolate was prepared in ratios of 1:1 and 1:2.In each 
case, the solid dispersions was characterized by FT-IR , DSC ,PXRD.   FT-IR 
Spectroscopy , DSC  &PXRD. Showed a change in crystal structure toward an 
amorphous form of furosemide .Dissolution data indicated that furosemide dissolution 
was enhanced.  
 Yogesh Pore et al.,2009.  Physicochemical characterization of solid dispersion 
systems of Tadalafil with Poloxamer 407.  Solid dispersion systems of Tadalafil were 
prepared with Poloxamer 407 in 1:0.5, 1:1.5 and 1:2.5 ratios using the melting method. 
Characterization of binary systems with FTIR and XRPD studies demonstrated the 
presence of strong hydrogen bonding interactions, a significant decrease in 
crystallinity and the possibility of existence of amorphous entities of the drug. In the 
binary systems tested, 1:0.5 proportion of Tadalafil/Poloxamer 407 showed rapid 
dissolution of tadalafil. 
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Tang Xing et al.,2008.  Nimodipine semisolid capsules containing solid dispersion for 
improving dissolution. Preparation of a solid dispersion consisting ofNimodipine , 
Eudragit E100& Plasdone-S630 by hot melt extrusion method. Compared with 
physical mixture and pure drug ,the dissolution of nimodipine was enhanced 
dramatically ( about 80% within 30 mins ) using Powder X Ray Diffraction study, and 
DSC analysis, both Eudragit E 100 and Plasdone – S630 were found to be compatible 
with nimodipine in the solid dispersion system.  
 Nagasamy venkatesh. D et al.,2008.  Dissolution enhancement of domperidone using 
water soluble carrier by solid dispersion technique. Solid dispersions of domperidone 
were prepared using different ratio of PVP K30 as carrier by kneading method. They 
were evaluated for drug content, intactness of the drug in the formulation and 
dissolution. IR Spectral and DSC studies were used to characterize the solid dispersion 
and to study the possibility of complexation of drug with carrier .The dissolution of 
domperidone from the solid dispersion exhibited higher rates of dissolution and 
dissolution efficiency values over that of pure drug.  
Lynne S. Taylor et al.,2008.   Effect of polymer type on the dissolution profile of 
amorphous solid dispersions containing felodipine using HPMC acetate succinate, 
PVP K30 & HPMC 606 by solvent evaporation method. The dissolution behavior of 
amorphous solid dispersions of felodipine prepared with PVP, HPMC and HPMCAS 
has been compared. Solid dispersions formulated with HPMCAS were found to result 
in solutions with the highest extent of supersaturation, whereas HPMC and PVP were 
less effective. At equivalent supersaturations, all three polymers were observed to 
reduce crystal growth rates relative to the growth rate of the drug alone. HPMCAS and 
HPMC were most effective at inhibiting growth rates while PVP was much less 
effective. These results indicate that it is important to select the appropriate polymer 
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for a solid dispersion after considering both the solid state stability and the stability of 
the supersaturated solution generated following dissolution of the amorphous. 
 Ganesh Chaulang et al., 2008. Preparation and Characterization of Solid Dispersion 
Tablet of Furosemide with Crospovidone 1:1 (w/w) and 1:2 (w/w) solid dispersions 
were prepared by kneading method using solvent water and ethanol in 1:1 ratio. 
Dissolution studies using the USP paddle method were performed for solid dispersions 
of furosemide at 37 ± 0.5oC and 50 rpm in simulated gastric fluid (SGF) of pH 1.2.  
FTIR spectroscopy, DSC and X-ray diffractometry were performed to identify the 
physicochemical interaction between drug and carrier, hence its effect on dissolution. 
 Hoo – Kyun – Choi et al., 2006.  Preparation of a solid dispersion of Felodipine by 
solvent wetting method using various polymeric carriers like PVP, HPMC, 
Poloxamer,Mannitol & sorbitol. The results of DSC & PXRD studies showed that 
felodipine in solid dispersion exists in the amorphous state in PVP , HPMC and 
Poloxamer , but not when sorbitol or mannitol used as carriers. The dissolution rate of 
felodipine from PVP,HPMC &Poloxamer solid dispersions was markedly higher than 
from their corresponding physical mixtures.  
Toshio Ohara et al., 2005.  Dissolution mechanism of poorly water soluble drug from 
extended release solid dispersion system with Ethyl cellulose and Hydroxy propyl 
methyl cellulose. Indomethacin was used as a model of poorly water soluble drug. To 
investigate the release mechanism of poorly water soluble drug from the extended 
release solid dispersion system with water insoluble EC and water soluble HPMC    
(1:1 ) by suspending method and dissolving method.  
 Yalcin Ozkan et al.,2000. Enhanced release of solid dispersions of Etodolac in 
polyethylene glycol. Solid dispersions of etodolac were prepared in different molar 
ratios of drug : carrier by using solvent and melting methods. The release rate of 
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etodolac from the resulting complexes was determined from dissolution studies by use 
of USP dissolution apparatus 2 (paddle method). The physical state and drug : PEG 
interaction of solid dispersions and physical mixtures were characterized by X-ray 
diffraction (XRD), infrared spectroscopy (IR) and differential scanning calorimetry 
(DSC). The dissolution rate of etodolac is increased in all of the solid dispersion 
systems compared to that of the pure drug and physical mixtures. The solid dispersion 
compound prepared in the molar ratio of 1:5 by the solvent method was found to have 
the fastest dissolution profile. 
Abu T.M Serajuddin et al.,2000. Bioavailability enhancement of a poorly water-
soluble drug by solid dispersion in polyethylene glycol–polysorbate 80 mixture . Two 
solid dispersion formulations of the drug, one in Gelucire 44/14® and another one in a 
mixture of polyethylene glycol 3350 (PEG 3350) with polysorbate 80, were prepared 
by dissolving the drug in the molten carrier (65 ◦C) and filling the melt in hard gelatin 
capsules. From the two solid dispersion formulations, the PEG 3350–polysorbate 80 
was selected for further development. The oral bioavailability of this formulation in 
dogs was compared with that of a capsule containing micronized drug blended with 
lactose and microcrystalline cellulose and a liquid solution in a mixture of PEG 400, 
polysorbate 80 and water. For intravenous administration, a solution in a mixture of 
propylene glycol, polysorbate 80 and water was used. Absolute oral bioavailability 
values from the capsule containing micronized drug, the capsule containing solid 
dispersion and the oral liquid were 1.7 ± 1.0%, 35.8 ± 5.2% and 59.6 ± 21.4%, 
respectively. Thus, the solid dispersion provided a 21-fold increase in bioavailability 
of the drug as compared to the capsule containing micronized drug. A capsule 
formulation containing 25 mg of drug with a total fill weight of 600 mg was 
subsequently selected for further development. The selected solid dispersion 
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formulation was physically and chemically stable under accelerated storage conditions 
for at least 6 months. It is hypothesized that polysorbate 80 ensures complete release 
of drug in a metastable finely dispersed state having a large surface area, which 
facilitates further solubilization by bile acids in the GI tract and the absorption into the 
enterocytes. Thus, the bioavailability of this poorly water-soluble drug was greatly 
enhanced by formulation as a solid dispersion in a surface-active carrier 
Maria Victoria Margarit et al.,1994.   Physical characteristic and dissolution kinetics 
of solid dispersions of Ketoprofen and PEG 6000. To prepare solid dispersions of 
Ketoprofen and PEG6000 , compared the dissolution kinetics of the solid dispersion 
with physical mixture and pure drug.Physio-chemical characters were determined by 
PXRD & DSC. The carrier PEG6000 effectively improves ketoprofen solubilization 
with 10:90 (drug:polymer) solid dispersion showing best dissolution kinetics. 
Valsartan in Solid Dispersions with β-CD,HP β-CD, and PVP K-30. Solid dispersions 
and physical mixtures  of valsartan in β-cyclodextrin , hydroxypropyl β-cyclodextrin , 
and polyvinyl pyrollidone  were prepared to increase its solubility characteristics. The 
drug formulations were characterized in the solid state by Fourier transform infrared 
spectroscopy (FTIR) and differential scanning calorimetry (DSC). By these physical 
determinations, drug–polymer interactions were found. Both the solubility and the 
dissolution rate of the drug in these formulations were increased. Drug contents were 
determined by UV spectrophotometry at a λmax of 249.5 nm.. The SDs of valsartan 
with β-CD and HP β-CD were prepared at 1:1, 1:3, and 1:5 drug/carrier ratios by a 
kneading method, and PVP K-30 SDs were prepared at the same ratios (i.e., 1:1, 1:3 
and 1:5 drug/carrier) by a lyophilization technique. The FTIR spectroscopic studies 
show the stability of valsartan and the absence of well-defined drug–polymer 
interaction. Compared with β-CD, HP β-CD showed better enhancement of dissolution 
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rate; compared with HP β-CD, PVP K-30 showed better solubility and dissolution 
enhancement. 
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                                             CHAPTER-IV 
                                        AIM OF THE WORK 
            The aim of present work, an attempt was made to improve the solubility and 
dissolution rate of a poorly water soluble drug, Racecodotril.   
       Racecadotril, also known as acetorphan, is chemically known as 
Benzyl[[(2RS)-2-[(acetylsulfanyl)methyl]-3-phenylpropanoyl]amino]acetate, which is 
a prodrug of the enkephalinase inhibitor thiophan. It is an antidiarrheal drug which act 
as a peripherally acting enkephalinase inhibitor. (Sasmita kumara acharijya et 
al.,2010) . 
     Racecadotril, practically insoluble in water, freely soluble in methanol and in 
methylenechloride (British pharmacopoeia 2009).  
Solubility is an important physicochemical factor affecting absorption of drug 
and it’s the therapeutic effectiveness. Consequences of poor aqueous solubility would 
lead to failure in formulation development. The poor solubility of drug substances in 
water and their low dissolution rate in aqueous G.I.T fluid often leads to insufficient 
bioavailability. Solid dispersions are prepared using PEG 6000, PVP k30 and 
Poloxamer 188 to increase its aqueous solubility. Racecadotril solid dispersion are 
prepared in  1:1, 1:2, 1:3 and 1:4 ratios of the drug and carrier ratio (by weight) using 
kneading, melting, solvent evaporation and freeze drying methods. 
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CHAPTER-V 
PLAN OF WORK 
 
PART I 
1. Determination of   λmax   of  Racecadotril 
2. Calibration Curve for the drug in Acid buffer  PH 1.2    
 
PART- II     
1.  Fourier Transform -Infra Red (FT- IR) studies to determine the 
interaction between carriers with drug. 
2. Differential scanning calorimetry (DSC) studies of selected 
formulations to determine the status of the drug and carrier. 
                  
PART-III 
1. Formulation of Solid Dispersions of Racecadotril using different ratios of 
carriers by Melting method, Solvent evaporation method, Kneading method 
Freeze drying method and physical mixing method. 
 
PART-IV 
1. Determination of drug content of all the formulations 
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PART -V 
1. In-vitro release profile of the formulated solid dispersions by using 
acid buffer pH 1.2 as dissolution medium in USP-type-I method (Basket type) at 
37
0
 C,    100 rpm. 
PART-VI 
1. Powder X-Ray Diffraction (PXRD) studies of selected formulations 
(solid dispersion, physical mixture and pure drug) to determine crystallinity of 
the drug. 
2. Solubility studies to determine the solubility of solid dispersion of         
Racecadotril, physical mixture and pure drug using distilled water and 
dissolution medium. 
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                                                  CHAPTER-VI 
                                   MATERIALS AND EQUIPMENTS 
 
                 
 
 
 
 
 
 
MATERIALS 
 
SUPPLIERS 
 
     Racecadotril   (Pure drug ) 
 
Gift Sample from Safe Tab Life 
Science Ltd Pondicherry.          
  
                PEG 6000 
 
S.D. Fine Chem Ltd -   Mumbai 
 
                PVP K 30 
 
Nice Chemicals,kochi. 
 
             Poloxamer 188 
 
Nice Chemicals,kochi. 
 
           Potassium chloride 
 
Central Drug House ,Newdelhi. 
 
           Hydrochloric acid 
 
Nice Chemicals,kochi. 
 
                   Methanol 
 
Astron Chemicals,Ahmedabad. 
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                                             EQUIPMENTS 
 
EQUIPMENTS 
 
SUPPLIERS 
 
    UV-Spectrophotometer 
 
 
Shimadzu pharma spec    UV-1700 
 
    Dissolution Apparatus 
 
Labindia   - Disso 8000, New Mumbai. 
 
             Water Bath 
 
M.C.Dalal & co, Chennai. 
 
           Electronic Balance 
 
A & D   Company. Japan 
 
            Hot Air Oven 
 
Rands  Instrument Company, Chennai. 
 
        Rotary Flask Shaker 
 
Secor , India 
 
Differential Scanning    
Colorimeter 
 
DSC 200  TA Instrument , USA 
 
Fourier Transform- Infra Red 
Spectroscopy 
 
      Perkin – Elmer, Germany. 
  
             Freeze  Dryer 
 
  
Powder X Ray             
Diffractometer 
      
        XD, Shimadzu, Japan 
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CHAPTER-VII 
DRUG PROFILE 
RACECADOTRIL 
 
   SYNONYM: 
                           Acetorphan 
 
   STRUCTURE 
          
   FORMULA: 
                                           C21H23NO4S 
   MOLECULAR WEIGHT: 
                                            385.5 
 
 
    SYSTEMATIC IUPAC NAME: 
 
Benzyl[[(2RS)-2-[(acetylsulfanyl)methyl]-3-                            
phenylpropanoyl]amino]acetate                        
CHAPTER-VII                                                                                 DRUG PROFILE 
 
SOLID DISPERSION Page 48 
 
 APPEARANCE: 
                             White or almost white powder 
     SOLUBILITY: 
             Practically insoluble in water , freely soluble in methanol and in 
methylene chloride. (British Pharmacopoeia, 2009) 
 MELTING POINT: 
                                                               89º c  
     pka: 
                                                               13.63 
     PARTITION COEFFICIENT: 
                                                               3.44 
     HALF LIFE: 
                                                               3  Hours  
     ROUTE OF ADMINISTRATION: 
                                                              Oral 
       
   DOSE: 
                                                               100 mg  -  b.i.d - adult 
                                                               1.5 mg / kg  - children 
 
      
   DOSAGE  FORM : 
                                                       Capsules/ tablets    ---   100 mg 
                                                       DT Tablets            ---    10,30  mg 
                                                        Sachet                  ---    1g, 1.5g ,3g 
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    USE: 
                                                             Antidiarrhoeal 
 
    PHARMACOLOGY: 
                Racecadotril is a lipophilic derivative of thiorphan. Racecadotril is  rapidly 
converted in the body to thiorphan,a potent enkephalinase inhibitor. 
                 Enhephalins  are endogenous opioid  peptides secreted by myenteric and 
submocosal neurons in the digestive tract. 
                     The enkephalins by activating the  opioid receptor , inhibit the secretion 
of cl- and fluids Thus reducing the loss of fluids and electrolytes during diarrhoea. The 
antisecretory mechanisms are independent of effects on intestinal motility, 
differentiating this compound from µ -opiate receptor  agonists like loperamide & 
diphenoxylate.  
 
  PHARMACOKINETICS 
               Racecadotril is administered by the oral route , is well absorbed from the 
intestinal tract and is rapidly converted to its active metabolite thiorphan. Peak plasma 
levels are attained in about an hour and half life of the drug is 3 hours. 
                 Data on safety in pregnancy,lactation and renal / hepatic insufficiency is 
inadequate , which requires care in the usage.     
 
    CLINICAL USES 
                                        Racecadotril is the first truly intestinal antisecretory drug to                
treatment of  diarrhoea. 
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    ADVERSE EFFECT 
                                       Fewer patients on racecadotril therapy suffered from 
abdominal distension following treatment . 
                                         It caused significantly less constipation ,incidence  of 
itching, nausea, vomiting ,thirst, vertigo and head ache.( CIMS) 
                                          Racecadotril does not enter the CNS, thus it lacks any 
potential for neurotoxicity; however in children below 2 years of age where blood 
brain barrier is immature it can cause depression.(Lt col N.Singh et al.,2008) 
                                        
CHAPTER –VIII                                                      EXCIPIENT PROFILE 
 
SOLID DISPERSION Page 51 
 
CHAPTER-VIII 
EXCIPIENT PROFILE 
POLYETHYLENE GLYCOL 6000 
(PEG 6000) 
  
SYNONYMS 
Carbowax ,  Carbowax Sentry,   Lipoxol,  Lutrol E,  PEG, Pluriol E  ,   
polyoxyethylene glycol 
. 
CHEMICAL NAME 
α-Hydro-ώ-hydroxypoly(oxy-1,2-ethanediyl) 
 
EMPIRICAL FORMULA 
 
HOCH2 (CH2OCH2) mCH2OH     
where m represents the average of oxyethylene            
groups 
 
MOLECULAR WEIGHT 
                                                                       6000 
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STRUCTURAL FORMULA 
                                                                                                            
            
FUNCTIONAL CATEGORY 
Ointment base, plasticizer, solvent, suppository base, tablet and capsule 
lubricant. 
 
DESCRIPTION 
Polyethylene glycol grades 200̽600 are liquids , grades 1000 and above are 
solids at ambient temperatures. Liquid grades occur as clear, colorless or slightly 
yellow-colored, viscous liquids. They have a slight but characteristic odor and a bitter, 
slightly burning taste. PEG 600 can occur as a solid at ambient temperatures. Solid 
grades are white or off-white in color, and range in consistency from pastes to waxy 
flakes. They have a faint, sweet odor. Grades of PEG 6000 and above are available as 
free-flowing milled powders. 
 
TYPICAL PROPERTIES 
DENSITY: 
                      1.11̽1.14 g/cm3 at 25 0 C for liquid PEGs 
                      1.15̽1.21 g/cm3 at 25 0 C for solid PEGs. 
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MELTING POINT: 
                      55̽63 0 C for PEG 6000 
 
SOLUBILITY: 
All grades of polyethylene glycol are soluble in water . Liquid polyethylene 
glycols are soluble in acetone, alcohols, benzene, glycerin, and glycols. Solid 
polyethylene glycols are soluble in acetone, dichloromethane, ethanol (95%), and 
methanol; they are slightly soluble in aliphatic hydrocarbons and ether, but insoluble 
in fats, fixed oils, and mineral oil. 
 
SURFACE TENSION: 
Approximately 55mN/m (55 dynes/cm) for 10% w/v aqueous solution of solid 
polyethylene glycol. 
 
VISCOSITY  ( mm
2
/s (Cst) at 25
0 
C   : 580 
 
FREEZING POINT ( 
0
C )      :  56 – 61 
 
PH (5%W/V SOLUTION)     : 4.5 – 7.5 
 
RESIDUE ON IGNITION     :  ≤0.25% 
 
HYDROXYL VALUE     : 16 -22 
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METHOD OF MANUFACTURE: 
Polyethylene glycols are condensation polymers formed by the reaction of 
ethylene oxide and water under pressure in the presence of a catalyst. 
 
STORAGE CONDITIONS: 
Polyethylene glycols should be stored in well-closed containers in a cool, dry 
place. Stainless steel, aluminum, glass, or lined steel containers are preferred for the 
storage of liquid grades. 
 
HANDLING PRECAUTIONS 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection is recommended 
 
SAFETY 
Polyethylene glycols are widely used in a variety of pharmaceutical formulations. 
Generally, they are regarded as nontoxic and nonirritant materials. Adverse 
reactions to polyethylene glycols have been reported, the greatest toxicity being 
with glycols of low molecular weight. However, the toxicity of glycols is relatively 
low. (Raymond C Rowe et al.,2006) 
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SOLID DISPERSION 
 
                                        
SYNONYMS 
Lutrol, Monolan 
copolymer,   polyoxyethy
 
CHEMICAL NAME 
 
EMPIRICAL FORMU
                                        
 
02/(&8/$5:(,*+7


STRUCTURAL FORM
                                        
 
FUNCTIONAL CATEG
Dispersing agent
tablet lubricant; wetting 
 
                                                    EXCIPIEN
             POLOXAMER  188 
, Pluronic , poloxalkol , polyethylene
lene̽polyoxypropylene copolymer, Suproni
α-Hydro-ώhydroxypoly(oxyethylene)pol
poly(oxyethylene) block copolymer 
LA 
          HO(C2H4O)a(C3H6O)b(C2H4O)aH.


ULA 
                         
ORY 
; emulsifying and coemulsifying agent; 
agent. 
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̽propylene glycol 
c; Synperonic. 
y(oxypropylene) 
 
 
solubilizing agent;           
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APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
Poloxamers are nonionic polyoxyethylene̽polyoxypropylene copolymers used 
primarily in pharmaceutical formulations as emulsifying or solubilizing agents. 
Poloxamers are used as emulsifying agents in intravenous fat emulsions, and as 
solubilizing and stabilizing agents to maintain the clarity of elixirs and syrups. 
Poloxamers may also be used as wetting agents; in ointments, suppository bases and 
gels; and as tablet binders and coatings. Poloxamer 188 has also been used as an 
emulsifying agent for fluorocarbons used as artificial blood substitutes and in the 
preparation of solid-dispersion systems. 
 
DESCRIPTION 
Poloxamers generally occur as white, waxy, free-flowing prilled granules, or as 
cast solids. They are practically odorless and tasteless. 
 
WEIGHT % OXYETHYLENE 
                                                                         81.8  ±  1.9 
pH (aqueous solution ) 
                                                                         5 – 7.5 
UNSATURATION ( mEq / g ) 
                                                                        0.026  ±  0.008 
DENSITY 
                                                                        1.06 g /cm
3  
at 25 
0 
c 
FLASH POINT 
                                                                        260 
0 
c 
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FLOWABILITY 
                                                                        Solid poloxamers are free flowing 
HLB VALUE 
                                                                      29 
SOLUBILITY 
                                                                    Freely soluble in water and ethanol ( 95 % ) 
SURFACE TENSION 
19.8mN/m (19.8 dynes/cm) for a 0.1% w/v aqueous poloxamer 188 
solution at  25 
0
C 
 
VISCOSITY (DYNAMIC) 
1000 mPa s (1000 cP) as a melt at 77 
0
C for poloxamer 188.  
 
STABILITY AND STORAGE CONDITIONS 
Poloxamers are stable materials. Aqueous solutions are stable in the presence of 
acids, alkalis, and metal ions. However, aqueous solutions support mold growth. The 
bulk material should be stored in a well-closed container in a cool, dry place. 
 
INCOMPATIBILITIES 
Depending on the relative concentrations, poloxamer 188 is incompatible with 
phenols and parabens. 
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METHOD OF MANUFACTURE 
Poloxamer polymers are prepared by reacting propylene oxide with propylene 
glycol to form polyoxypropylene glycol. Ethylene oxide is then added to form the 
block copolymer. 
 
SAFETY 
Poloxamers are used in a variety of oral, parenteral, and topical pharmaceutical 
formulations and are generally regarded as nontoxic and nonirritant materials. 
Poloxamers are not metabolized in the body. 
 
HANDLING PRECAUTIONS 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and gloves are recommended (Raymond C Rowe et 
al.,2006) 
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POLY VINYL PYROLLIDINE  K30 
( PVP K30 ) 
 
SYNONYMS 
E1201, Kollidon, Plasdone, poly[1-(2-oxo-1-pyrrolidinyl)ethylene], polyvidone, 
povidone  , 1-vinyl-2-pyrrolidinonepolymer 
 
CHEMICAL NAME 
                              1-Ethenyl-2-pyrrolidinone homopolymer 
 
EMPIRICAL FORMULA 
                             (C6H9NO)n 
 
MOLECULAR WEIGHT 
                                            50000 
STRUCTURAL FORMULA 
 
 
FUNCTIONAL CATEGORY 
Disintegrant; dissolution aid; suspending agent; tablet binder 
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TYPICAL PROPERTIES 
ACIDITY/ALKALINITY:                  pH = 3.0̽7.0 (5% w/v aqueous solution). 
 
DENSITY (bulk):                                 0.29̽0.39 g/cm3 
 
DENSITY (tapped):                              0.39̽0.54 g/cm3 
 
DENSITY (true):                                 1.180 g/cm3 
 
FLOWABILITY:                               16 g/s for PVP  K-29/32. 
 
MELTING POINT:                            softens at 150 
0 
C 
 
DYNAMIC VISCOSITY (mpa s) 
PVP  K-30 3.4 ( Ethanol 95 % )    
5.8 ( Propane -2 – ol )  
 
MOISTURE CONTENT: 
povidone is very hygroscopic, significant amounts of moisture being absorbed 
at low relative humudities. 
 
SOLUBILITY: 
Freely soluble in acids, chloroform, ethanol (95%),  ketones, methanol, and 
water, practically insoluble in ether, hydrocarbons, and mineral oil. In water, the 
concentration of a solution is limited only by the viscosity of the resulting solution, 
which is a function of the K-value.  
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APPLICATIONS IN PHARMACEUTICAL FORMULATION OR 
TECHNOLOGY 
 Carrier for drugs 
 Dispersing agent 
 Eye drops 
 Suspending agent 
 Tablet binder, tablet diluent, or coating agent 
 
DESCRIPTION 
PVP occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. PVPs with K-values equal to or lower than 30 are 
manufactured by spray-drying and occur as spheres. PVP K-90 and higher K-value 
PVPs are manufactured by drum drying and occur as plates. 
 
INCOMPATIBILITIES 
PVP is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other 
chemicals. It forms molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic acid, phenobarbital, tannin, and other compounds. The efficacy of some 
preservatives, e.g. thimerosal, may be adversely affected by the formation of 
complexes with PVP. 
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METHOD OF MANUFACTURE 
PVP is manufactured by the Reppe process. Acetylene and formaldehyde are 
reacted in the presence of a highly active copper acetylide catalyst to form butynediol, 
which is hydrogenatedto butanediol and then cyclodehydrogenated to form 
butyrolactone. Pyrrolidone is produced by reacting butyrolactone with ammonia. This 
is followed by a vinylation reaction in which pyrrolidone and acetylene are reacted 
under pressure. 
The monomer, vinylpyrrolidone, is then polymerized in the presence of a combination 
of catalysts to produce PVP. 
 
SAFETY 
PVP is widely used as an excipient, particularly in oral tablets and solutions. 
When consumed orally,  PVP may be regarded as essentially nontoxic since it is not 
absorbed from the gastrointestinal tract or mucous membranes. PVP additionally has 
no irritant effect on the skin and causes no sensitization. 
 
HANDLING PRECAUTIONS 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves, and a dust mask are recommended. 
(Raymond C Rowe et al.,2006) 
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CHAPTER-IX 
 EXPERMENTAL DETAILS 
I. CALIBRATION OF RACECADOTRIL 
a) Preparation of dissolution medium:   
i. Hydrochloric acid buffer pH 1.2: 
      50 ml of 0.2 M Potassium chloride is placed in a 200 ml volumetric flask.  85 ml 
of 0.2 M Hydrochloric acid is added and made up to the volume with distilled water. 
(Indian pharmacopoeia 1996) 
ii. 0.2 M Potassium Chloride 
      14.911 g of Potassium chloride is dissolved with distilled water and the volume 
is made up to 1000 ml. 
iii. 0.2M Hydrochloric acid  
      7.292 g of Hydrochloric acid is diluted to 1000 ml with the distilled water.  
b) CALIBRATION CURVE OF RACECADOTRIL: 
                An accurately weighed   quantity of 100 mg of Racecadotril pure drug is 
taken into a clean dried 100ml volumetric flask dissolved in methanol and made upto 
100ml with methanol. From this 10ml of the solution is pipette out and volume made 
upto 100ml with acid buffer solution ph 1.2. From this 5,10,15,20 & 25 ml are pipetted 
out and diluted to 100ml with acid buffer solution pH 1.2. Absorbance are measured at 
232 nm using the acid buffer solution as blank by U-V Spectrophotometer. 
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II. PREFORMULATION (COMPATABILITY) STUDIES: 
a) Differential Scanning Calorimetry (DSC) Studies: 
DSC analysis (DSC200 TA instruments,USA) of the samples are carried out on a 
samples are heated under nitrogen atmosphere on an aluminium pan at a heating rate of 
10℃	/min. Over the temperature range 5-200℃. DSC analysis is carried out under 
nitrogen gas flow of 20 lb/cm
2
. (Anshu Sharma et al., 2010) 
b) Fourier Transform Infra-Red (FT-IR) studies: 
  While studying the new formulation it is necessary to check the compatibility 
with the carrier or excipient used and has not undergone degradation. FT-IR spectra 
(Spectrum RX-1 Perkin-Elmer, German) for the drug and various physical mixtures are 
obtained in a FT-IR spectroscopy in the transmission mode with the wave number 
region 4000-400cm
-1
.
 
KBr pellets are prepared by gently mixing 1mg sample powder 
with 100mg KBr. (S.K Swain et al., 2010)  
III. PREPARATION OF SOLID DISPERSION OF RACECADOTRIL 
Solid dispersion of Racecadotril is prepared by following methods, 
                               A. Melting method. 
                               B. Kneading method.   
                               C. Solvent evaporation method. 
                               D. Freeze drying method. 
                               E. Preparation of physical mixture   
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A) MELTING METHOD 
                  Water soluble carriers (PEG 6000 & Poloxamer 188) are taken in a china 
dish and heated at 60ºc in a water bath, until the mixture melts completely. The drug 
(Racecadotril) is added to the molten polymer and mixed thoroughly. The dispersion is 
cooled to ambient condition. Solidified mass is crushed, pulverized and passed through 
sieve no 120, and stored in a desiccator. (Anshu Sharma et al., 2010) 
B) KNEADING METHOD 
                            A mixture of drug (Racecadotril) and  carriers (PEG 6000, PVP K30 
& Poloxamer 188) in different ratio  (1:1,1:2,1:3,1:4) are wetted with solvent 
(methanol) and water (1:1 ratio) , and kneaded thoroughly for 30 minutes in a glass 
mortar. The paste formed is dried under vacuum for 24 hours.  Dried powder is 
scrapped, crushed, pulverized and passed through sieve no 120 and stored in desiccator. 
(D.Nagasamy venkatesh et al., 2008) 
C) SOLVENT EVAPORATION METHOD   
      Racecadotril solid dispersions are prepared by solvent evaporation method 
using carrier PVP K30 in proportions viz., (1:1, 1:2, 1:3, and 1:4).The drug and carrier 
are dissolved in methanol in a china dish and the mixture is heated until the solvent 
evaporated and clear film of drug and carrier is obtained. The resultant solid dispersion 
is scraped out with a spatula .Dispersions are pulverized in a mortar and pestle and 
passed through a 125µm sieve before packing in an airtight container.(Kothawade S.N 
et al., 2010) 
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D) FREEZE DRYING METHOD 
                          Hydrophilic carrier (PVP K30) is dissolved in organic solvent, poorly 
water soluble drug (Racecadotril) is added to this separately and dissolved. The 
resulting ternary system of organic solvent, hydrophilic carrier and drug is freeze dried 
by filling glass vials with the solutions and positioning the vials in a lyophilizer. During 
operation, the freeze dried is maintained at -45 c and a compressional pressure of 0.5 
torr. After complete drying, the vials are taken out, and the dried products are scraped 
from the vials. The formulations are powdered and packaged in glass vials. (Anjan K. 
Mahapatral et al., 2008) 
E)  PREPARATION OF PHYSICAL MIXTURE 
                             The physical mixture is prepared by mixing of drug and carrier in 
a glass mortar. Solid mass is pulverized and passed through sieve no 120 to get uniform 
sized particles. (Venkatesh Kumar. K et al., 2009) 
IV. CHARACTERIZATION OF SOLID DISPERSION 
a) Estimation of drug content 
b) In-vitro dissolution studies 
c) Solubility studies 
d) Powder X- ray diffraction studies (PXRD) 
a) Estimation of Drug Content 
                                    Physical mixtures and solid dispersions equivalent to 10mg 
of racecadotril are weighed accurately and dissolved in 10ml of methanol. The 
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solution is filtered, diluted suitably with acid buffer ph 1.2 and drug content is 
analyzed at 232 nm by UV –Spectrophotometer. (Appa Rao. B et al., 2010) 
                                                         Sample absorbance 
     %   drug content =         ----------------------------------------   X 100 
                                                       Standard absorbance  
b) In-vitro Dissolution Studies 
Dissolution study is carried out by using USP rotating basket (Apparatus-I) for 
1 hour, the stirring rate is 100rpm. Acid buffer pH 1.2 is used as dissolution medium 
(900ml) and temperature is maintained at 37± 0.5℃. Samples equivalent to 100mg of 
racecadotril is filled in hard gelatin capsules used for dissolution studies. Samples are 
collected at regular interval of time (5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60min). 
The absorbance of the samples is measured at ƛ max 232 nm after suitable dilution 
using appropriate blank. (Dehghan M H G et al., 2010)  
c) Solubility Studies: 
Solubility study is assessed out according to the method of Higuchi and 
Cannors. The solubility of racecadotril as pure drug, physical mixture and solid 
dispersion (KM 7) are determined in distilled water and acid buffer PH 1.2. Samples 
are equivalent to 10mg of drug is taken and to this 10ml of respective medium is being 
added in 250ml conical flask, and shaken for 24 hours at room temperature on Rotary 
Flask Shaker. The entire samples are protected from light by wrapping the flask by 
aluminum foil. After 24 hours samples are filtered through whatman filter paper and 
aliquots are suitably diluted and assayed by spectrophotometrically at 232nm.(Dehghan 
et al.,2010) 
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d) Powder X Ray Diffraction Studies (PXRD) 
             Powder X-ray diffraction patterns (XRD) of the pure drug, physical mixture 
(PM7) and solid dispersion (KM7)  were monitored with an X-Ray Diffractometer 
(XD, Shimadzu, Japan) using copper as x-ray target, a voltage of 40 KV, a current of 
30 mA and with 1.5404 Angstrom wavelength. The samples were analyzed over 2θ 
range of 7.02-59.980 with scanning step size of 0.020 (2θ) and scan step time of one 
second.(Amit R Tapas et al.,2010).  
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                                             CHAPTER-X 
                                 RESULTS AND DISCUSSION 
 
I. CALIBRATION OF RACECADOTRIL 
The λmax of Racecadotril was determined by scanning the 10µg/ml of the drug 
solution in acid buffer solution pH 1.2. It showed the λ max of 232 nm in methanol and 
acid buffer solution pH1.2(Fig 1-A). Linear correlation coefficient was obtained         
(r
2
 = 0.9993) for calibration of Racecadotril (Fig 1-B). (A. Laksmana Rao et al., 2010) 
       Racecadotril obeys the Beer
’
s law within the concentration range of 5-25 
µg/ml. (Table- 3) 
II. PREFORMULATION (COMPATABILITY) STUDIES: 
a) Differential Scanning Colorimetry (DSC) Studies  
                          The DSC thermograms of Racecadotril and of its physical mixtures 
are shown in Fig 34-40 . The sharp melting point peak of pure racecadotril appeared 
at 80.9
0
C, whereas no such peak was observed in physical mixtures (1:1) prepared 
with PEG6000, PVP K30 and Poloxamer 188, suggesting that racecadotril was 
molecularly dispersed and in an amorphous form.(Fig 34-40). (Hoo-Kyun choi et 
al., 2006). 
 
b) Fourier Transform Infra-Red (FT- IR) Studies 
              The FT-IR Spectra of Racecadotril and its binary systems with PVP K30, 
PEG6000 and Poloxamer 188 are present in Fig 27-33. Pure racecadotril spectra 
showed  sharp characteristic peaks at 3939.91, 3285.52, 1950.86, 1644.82, 1289.86, 
695.30 cm
-1.
.  All the above characteristic peaks appear in the spectra of all binary 
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systems are within the same wave number indicating no modification or interaction 
between drug and carrier. (Patel B et al., 2010)   
 
III. PREPARATION OF RACECADOTRIL SOLID DISPERSIONS: 
In the present study, 28 formulations of Racecadotril solid dispersions were 
prepared by using water soluble carriers like PEG6000, Poloxamer 188 and PVP K30, 
in the ratio of 1:1,1:2.1:3 and 1:4 in 4methods ( Melting method, Kneading method, 
Solvent evaporation method and Freeze drying method) (Table-4) .The prepared solid 
dispersions were found to be uniform and homogeneous in appearance.  
 PEG6000 and Poloxamer 188 were used in the preparation of both melting and 
kneading method (16 formulations), but PVP K30 used in the preparation of kneading 
method, solvent evaporation method and freeze drying method (12 formulations), 
because of its hygroscopic nature. (Anjan K. Mahapatra et al., 2011) 
 
IV. CHARACTERIZATION OF SOLID DISPERSION 
a) Estimation of Drug Content: 
                       The drug content in all the formulations was estimated 
spectrophotometrically at 232 nm (Shimadzu UV1700, Pharmspec, Japan). The drug 
content of the prepared solid dispersions was found to be in the range of 95 % to 
101.3% indicating the uniform distribution of drug in the formulation.  (Table -1) 
(Kumar Sandeep et al., 2011)   
b) In-vitro Release Studies: 
The In vitro dissolution studies of  Racecadotril from solid dispersions were  
performed by using USP Type I ( Basket ) dissolution apparatus in 900 ml of acid 
buffer pH1.2 at 37
0
 C± 0.5
0
 C at 100 rpm.10ml of samples were withdrawn regular 
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intervals of 5 minutes for 1 hour and the same volume of fresh dissolution  medium 
was replaced after every withdrawal. The withdrawn samples were diluted suitably and 
analyzed by UV- visible spectrophotometer at 232 nm.  (Ganesh Chaulang et al., 
2009) 
 The cumulative percentage drug release profile data obtained for all solid 
dispersion formulations are tabulated in Table no 5 to 14.  
In kneading method, 3 different carriers were used. The release profiles of 
PEG6000,in the ratios of 1:1, 1:2, 1:3, 1:4 were found to be 44.4% (KM1),                 
56.5%(KM2),  45.3%( KM3), 47.9 %( KM4)  after 1 hour (Fig -3).From the results, it 
was observed that KM2(1:2 ratio) exhibits maximum release of 56.5% and it was rated 
as the best formulation in kneading method using PEG6000. In case of PVP K30, in 
the ratios of 1:1, 1:2, 1:3, 1:4 were found to be 46.4%(KM5), 43.7%(KM6), 
72.7%(KM7), 52%(KM8) after 1 hour(Fig- 4) . From the results, it was observed that 
KM7(1:3 ratio) exhibits maximum release of 72.7% and it was rated as the best 
formulation in kneading method using PVP K30.The release profile of  Poloxamer 188 
in the ratios of 1:1 ,1:2, 1:3, 1:4 were found to be 57.5%(KM9), 57.3%(KM0), 
57.8%(KM11), 53.1 %(KM12) after 1 hour (Fig -5). From the results, it was observed 
that KM11(1:3 ratio) exhibits maximum release of 57.8% and it was rated as the best 
formulation in kneading method using Poloxamer 188. 
 
In melting method, two different carriers were used. The release profiles of 
PEG6000, in the ratios of 1:1, 1:2, 1:3, 1:4 were found to be 55.8%(MM1), 
59.7%(MM2), 57.7%(MM3), 46.6%(MM4)  after 1 hour (Fig -6). From the results, it 
was observed that MM2(1:2 ratio) exhibits maximum release of 59.7% and it was 
rated as the best formulation in melting method using PEG6000. In case of  
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Poloxamer188, in the ratios of 1:1, 1:2, 1:3, 1:4 were found to be 55.8%(MM5), 
52.5%(MM6), 51.3%(MM7), 50.7%(MM8) after 1 hour (Fig -7) .  From the results, it 
was observed that MM5(1:1 ratio) exhibits maximum release of 55.8% and it was 
rated as the best formulation in melting method using Poloxamer 188.  
                                 
  In Freeze drying method,   PVP K30 was used as a carrier. The release profiles 
of PVP K30 ,in the ratios of 1:1, 1:2, 1:3, 1:4 were found to be  47.4%(FD1), 
56%(FD2), 60.6%(FD3), 58.2%(FD4) after 1 hour (Fig -23). From the results it was 
observed that the release profile of FD3(1:3 ratio) is higher than the release profiles of 
other formulations in this method.           
In Solvent evaporation method, PVP K30 was used as a carrier. The release 
profiles of PVP K30 ,in the ratios  of 1:1, 1:2, 1:3, 1:4 were found to be 
69.4%(SEM1),  54.2%(SEM2),  63.2%(SEM3), 51.3%(SEM3) after 1 hour (Fig -24) . 
From the results it was observed that the release profile of SEM1(1:1 ratio) is higher 
than the release profiles of other formulations in this method.  
 
In 1:1 ratio, the solid dispersion prepared by using PVP K30 employing solvent 
evaporation method, was found to be the best with the release rate of 69.4%(SEM1)  at 
1 hour (Fig-11,15,19), compared with the release profile of 44.4%(KM1), 
46.4%(KM5), 57.5%(KM9), 55.8%(MM1 & MM5), 47.4%(FD1), 31.5%(PM1), 
43.1%(PM5), 47.8%(PM9). From the results it was observed that the release profile of 
SEM1 is higher than the release profiles of other formulations in this ratio.  
In 1:2 ratio, the solid dispersion prepared by using PEG6000 employing melting 
method, was found to be the best with the release rate of 59.7%(MM2)  at 1 hour     
(Fig-12,16,20), compared with the release profile of 56.5%(KM2), 43.7%(KM6), 
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57.3%(KM10), 52.5%(MM6), 56%(FD2), 54.2%(SEM2), 30.6%(PM2), 38.7%(PM6), 
52.3%(PM10). From the results it was observed that the release profile of MM2 is 
higher than the release profiles of other formulations in this ratio.  
 
In 1:3 ratio, the solid dispersion prepared by using PVP K30 employing 
kneading method, was found to be the best with the release rate of 72.7%(KM7)  at 1 
hour (Fig-13,17,21), compared with the release profile of 45.3%(KM3), 
57.8%(KM11), 57.7%(MM3), 51.3%(MM7), 60.6%(FD3), 63.2%(SEM3), 
42.4%(PM3), 40%(PM7), 52.2%(PM11). From the results it was observed that the 
release profile of KM7 is higher than the release profiles of other formulations in this 
ratio.  
In 1:4 ratio, the solid dispersion prepared by using PVP K30 employing freeze 
drying method, was found to be the best with the release rate of 58.2%(FD4)  at 1 hour 
(Fig-14,18,22), compared with the release profile of 47.9%(KM4), 52%(KM8), 
53.1%(KM12), 46.6%(MM4), 50.7%(MM8), 51.3%(SEM4), 45.9%(PM4), 
37.5%(PM8), 51.1%(PM12). From the results it was observed that the release profile 
of FD4 is higher than the release profiles of other formulations in this ratio. 
In vitro release studies reveal that there is marked increase in the dissolution 
rate of racecadotril from all the solid dispersions when compared to physical mixture 
and pure drug. 
From the in vitro drug release profile, it can be seen that formulation             
KM 7(Kneading method) containing PVP K30 (1:3 ratio of drug: carrier) showed 
higher dissolution rate 72.7% after 1hour, and so it was considered as the overall best 
formulation. 
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  The solid dispersion of Racecadotril was prepared by three different carriers 
namely PEG6000, PVP K30, Poloxamer 188, employing various techniques. From the 
result it was observed that, among the 3 carriers, PVP K30 was found to have greater 
released rate than other two carriers. 
                      PVP K30 > Poloxamer 188 > PEG 6000 
 
             The increase in dissolution of the drug in both, the physical mixtures and solid 
dispersions was reported because of the enhanced wettability, hydrophilic nature of the 
carriers and possibility of reduced crystallinity of the drug in the formulations. 
(Chaudhari P.D et al., 2011) 
                   But as the amount of PEG6000, PVP K30 and Poloxamer 188 were 
increased (1:4 ratio) in all formulation, the dissolution rate was decreased .This 
decrease in dissolution rate may be due to increased viscosity of coating materials. 
(Kothawade.S. et al., 2010) 
                               Drug release from the solid dispersion formulation (KM 7) was 
found to be significantly higher as compared with that of marketed Racecadotril 
capsules. (Gupta et al., 2011) (Table – 16) (Fig- 25) 
 
c) Solubility Studies:    
The solubility study was conducted with pure drug, physical mixture and solid 
dispersion (KM 7) using distilled water and acid buffer pH 1.2 shown in Table no 15.  
It was observed that the solid dispersion (0.344 mg/ml) (KM 7) has highest solubility 
compared to pure drug (0.103 mg/ml) and physical mixture (0.161 mg/ml) (PM7) in 
both distilled water and acid buffer pH 1.2. (Fig -26)  (Dehghan et al., 2010) 
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d) Powder X Ray Diffraction (PXRD) Studies: 
              The Powder X-Ray Diffraction patterns of solid dispersion of racecadotril 
(KM7) with the physical mixture (PM7) and pure drug shown in Fig 41-43. In the case 
of solid dispersion of racecadotril with PVP K30, no characteristic racecadotril peaks 
were observed. These results are confirmed that racecodotril was transferred from a 
crystal to an amorphous form upon dispersion by the kneading method. (Hoo-Kyun 
Choi et al.,2006). 
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TABLE -1 PERCENTAGE DRUG CONTENT 
S.NO FORMULATION CODE % DRUG CONTENT              
AVERAGE ±SD 
1.  KM 1 95.3 ± 2.72 
2.  KM 2 95 ± 2.40 
3.  KM 3 95.5 ± 3.31 
4.  KM 4 98.8 ± 3.67 
5.  KM 5 96.6 ± 1.40 
6.  KM 6 96.4 ± 1.04 
7.  KM 7 95.2± 2.00 
8.  KM 8 96.1± 0.37 
9.  KM 9 97± 2.33 
10.  KM 10 99.9± 4.83 
11.  KM 11 98.5± 0.75 
12.  KM 12 96.6± 0.99 
13.  MM 1 101.3± 1.68 
14.  MM 2 98.6± 1.68 
15.  MM 3 97.8± 2.14 
16.  MM 4 98.3± 5.80 
17.  MM 5 95.8± 1.40 
18.  MM 6 97.5± 1.30 
19.  MM 7 96.1± 2.72 
20.  MM 8 98.5± 2.72 
21.  FD 1 100.5± 1.68 
22.  FD 2 101.3± 3.69 
23.  FD 3 96.4± 3.17 
24.  FD 4 99.9± 2.89 
25.  SEM 1 97.2± 0.99 
26.  SEM 2 99.4±  1.04 
27.  SEM 3 99.6± 1.40 
28.  SEM 4 99.9± 1.34 
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TABLE - 2 PERCENTAGE YIELD 
29.  PM 1 96.5± 1.39 
30.  PM 2 95.3± 1.04 
31.  PM 3 98.6± 2.14 
32.  PM 4 96.4± 1.04 
33.  PM 5 100.2± 2.04 
34.  PM 6 99.4± 1.04 
35.  PM 7 98.8± 2.04 
36.  PM 8 98.3± 1.77 
37.  PM 9 100.2± 1.03 
38.  PM 10 98± 0.37 
39.  PM 11 96.2± 2.40 
40.  PM 12 95.3± 1.40 
S.NO FORMULATION CODE %  YIELD 
1.  KM 1 97.2 
2.  KM 2 98.5 
3.  KM 3 98.6 
4.  KM 4 99.1 
5.  KM 5 98.7 
6.  KM 6 98.4 
7.  KM 7 98.8 
8.  KM 8 85.6 
9.  KM 9 97.5 
10.  KM 10 85.4 
11.  KM 11 84.8 
12.  KM 12 99.3 
13.  MM 1 96.8 
14.  MM 2 94.4 
15.  MM 3 95.1 
16.  MM 4 99.1 
17.  MM 5 91.8 
18.  MM 6 98.9 
19.  MM 7 94.6 
20.  MM 8 87.5 
21.  FD 1 89.8 
22.  FD 2 87.3 
23.  FD 3 91.2 
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TABLE – 3       CALIBRATION OF RACECADOTRIL (pH 1.2) 
 
 
                                             
                                                                        
REGRESSION (R
2
) = 0.9993 
 
 
 
 
24.  FD 4 90.4 
25.  SEM 1 93.6 
26.  SEM 2 95.7 
27.  SEM 3 89.5 
28.  SEM 4 87.9 
29.  PM 1 99 
30.  PM 2 99.5 
31.  PM 3 99.6 
32.  PM 4 99.6 
33.  PM 5 99.5 
34.  PM 6 99.4 
35.  PM 7 99.6 
36.  PM 8 99.7 
37.  PM 9 99.2 
38.  PM 10 99.5 
39.  PM 11 99.5 
40.  PM 12 99.6 
 
S.NO 
 
CONCENTRATION (µg/ml) 
 
ABSORBANCE at 232 nm 
(Avg ± SD ) 
 
1 
 
5 
 
0.061±0.0016 
 
2 
 
10 
 
0.122±0.0016 
 
3 
 
15 
 
0.189±0.0016 
 
4 
 
20 
 
0.260±0.0016 
 
5 
 
25 
 
0.334±0.0020 
                                                                                                                                              TABLES 
 
SOLID DISPERSION Page 79 
 
 
TABLE – 4 FORMULATION CHART                                                         
S.NO FORMULATION 
CODE 
COMPOSITION RATIO METHOD 
1.  KM 1 DRUG : PEG 6000 
 
1:1 KNEADING 
2.  KM 2 DRUG : PEG 6000 
 
1:2 KNEADING 
3.  KM 3 DRUG : PEG 6000 
 
1:3 KNEADING 
4.  KM 4 DRUG : PEG 6000 
 
1:4 KNEADING 
5.  KM 5 DRUG : PVP K30 
 
1:1 KNEADING 
6.  KM 6 DRUG : PVP K30 
 
1:2 KNEADING 
7.  KM 7 DRUG : PVP K30 
 
1:3 KNEADING 
8.  KM 8 DRUG : PVP K30 
 
1:4 KNEADING 
9.  KM 9 DRUG : POLOXAMER 188 
 
1:1 KNEADING 
10.  KM 10 DRUG : POLOXAMER 188 
 
1:2 KNEADING 
11.  KM 11 DRUG : POLOXAMER 188 
 
1:3 KNEADING 
12.  KM 12 DRUG : POLOXAMER 188 
 
1:4 KNEADING 
13.  MM 1 DRUG : PEG 6000 
 
1:1 MELTING 
14.  MM 2 DRUG : PEG 6000 
 
1:2 MELTING 
15.  MM 3 DRUG : PEG 6000 
 
1:3 MELTING 
16.  MM 4 DRUG : PEG 6000 
 
1:4 MELTING 
17.  MM 5 DRUG : POLOXAMER 188 
 
1:1 MELTING 
18.  MM 6 DRUG : POLOXAMER 188 
 
1:2 MELTING 
19.  MM 7 DRUG : POLOXAMER 188 
 
1:3 MELTING 
20.  MM 8 DRUG : POLOXAMER 188 
 
1:4 MELTING 
21.  FD 1 DRUG : PVP K30 1:1 FREEZE 
DRYING 
22.  FD 2 DRUG : PVP K30 1:2 FREEZE 
DRYING 
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23.  FD 3 DRUG : PVP K30 1:3 FREEZE 
DRYING 
24.  FD 4 DRUG : PVP K30 1:4 FREEZE 
DRYING 
25.  SEM 1 DRUG : PVP K30 1:1 SOLVENT 
EVAPORATION 
26.  SEM 2 DRUG : PVP K30 1:2 SOLVENT 
EVAPORATION 
27.  SEM 3 DRUG : PVP K30 1:3 SOLVENT 
EVAPORATION 
28.  SEM 4 DRUG : PVP K30 1:4 SOLVENT 
EVAPORATION 
29.  PM 1 DRUG : PEG 6000 
 
1:1 GRINDING 
30.  PM 2 DRUG : PEG 6000 
 
1:2 GRINDING 
31. PM 3  DRUG : PEG 6000 
 
1:3 GRINDING 
32. PM 4 DRUG : PEG 6000 
 
1:4 GRINDING 
33. PM 5 DRUG : PVP K30 1:1 GRINDING 
34. PM 6  DRUG : PVP K30 1:2 GRINDING 
35. PM 7  DRUG : PVP K30 1:3 GRINDING 
36. PM 8 DRUG : PVP K30 1:4 GRINDING 
37. PM 9 DRUG : POLOXAMER 188 1:1 GRINDING 
38. PM 10 DRUG : POLOXAMER 188 1:2 GRINDING 
39. PM 11  DRUG : POLOXAMER 188 1:3 GRINDING 
40. PM 12 DRUG : POLOXAMER 188 1:4 GRINDING 
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TABLE - 5 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL 
USING PEG 6000 BY KEADING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 
PURE 
DRUG 
KM 1 (1:1) KM 2(1:2) KM 3(1:3) KM 4(1:4) 
5 5.6±4.90 16.6±1.11 8.85±0.35 11.8±1.06 13.5±0.61 
10 9.4±0.37 18.7±0.61 13.1±0.57 15.6±1.14 17.2±0.94 
15 11.5±1.06 21.6±0.65 20.4±0.61 19.1±1.39 23.7±1.11 
20 12.9±1.02 23.4±0.82 25.2±0.38 26.7±5.91 26.4±1.35 
25 15.3±0.98 25.1±1.67 38.4±1.39 32.1±3.55 35.5±0.82 
30 18.5±0.32 26.7±1.97 44.3±0.77 35.1±2.06 37.6±0.87 
35 22.5±0.60 29.6±2.37 46.9±0.49 36.7±2.08 39.8±0.98 
40 24.9±0.43 32.6±2.93 51.2±0.37 37.6±2.26 40.8±1.14 
45 25.6±0.70 34.9±2.93 54.8±0.35 39.7±2.05 42.6±0.61 
50 26.1±0.43 38.3±3.20 54.7±0.74 41.9±1.26 44.8±0.86 
55 27.4±0.05 41.6±2.14 55.7±0.49 43.7±1.31 46.6±0.90 
60 28.1±0.32 44.4±1.55 56.5±0.35 45.3±0.96 47.9±1.01 
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TABLE-6 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL 
USING PVP K30 BY KEADING METHOD 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 KM 5(1:1) KM 6(1:2) KM 7(1:3) KM 8(1:4) 
5 11.7 ± 0.53 13.5± 0.83 9.6 ± 0.61 13.3 ± 0.82 
10 15 ± 0.82 15.8 ± 0.53 13.4 ± 0.82 16.3 ± 0.82 
15 19.7 ± 1.35 18.7 ± 1.63 18.4 ± 0.63 22.6 ± 1.02 
20 22.3 ± 0.30 22.2 ± 1.63 23 ± 0.82 29.2 ± 0.79 
25 24.1 ± 0.79 24.6 ± 0.82 48.8 ± 1.74 36.4 ± 1.06 
30 28.6 ± 1.83 27.5 ± 0.35 53.6± 0.53 43.7 ± 0.59 
35 31.5 ± 1.63 30 ± 0.88 56.3 ± 0.53 49.9 ± 0.83 
40 34.7 ± 2.79 32.9 ± 0.82 60.4± 0.83 51.7 ± 0.70 
45 37.7 ± 3.36 36.3 ± 0.61 64.4 ± 0.83 51.5 ± 0.57 
50 40.9 ± 2.30 38.5 ± 0.49 67.3 ± 0.35 51.8 ± 0.82 
55 44.2 ± 1.18 40.8 ± 0.57 70 ± 0.63 52.3 ± 0.83 
60 46.4 ± 0.91 43.7 ± 0.63 72.7 ± 0.35 52± 0.82 
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TABLE -7 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL USING 
POLOXAMER 188 BY KEADING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 KM 9 KM 10 KM 11 KM 12 
5 11.1 ± 0.53 14.8 ± 0.79 11.1 ± 0.53 14 ± 0.82 
10 19.8 ± 1.43 20.3 ± 0.28 13.8 ± 0.53 16.7 ± 1.14 
15 28.1 ± 1.35 25.7 ± 1.66 20.2 ± 0.82 20.9 ± 0.82 
20 31.7 ± 0.32 29.5 ± 0.94 27.2 ± 0.63 25.5 ± 1.88 
25 36.7 ± 1.15 35.8 ± 1.06 34.3 ± 0.57 31.9 ± 2.69 
30 45.4 ± 3.36 39.9 ± 1.74 41.9 ± 0.57 38.4 ± 4.01 
35 50.7 ± 1.96 45.1 ± 0.61 48.2 ± 0.53 43.2 ± 4.12 
40 55.2 ± 0.41 49.2 ± 0.35 50.1 ± 0.57 49.4 ± 2.40 
45 57.1 ± 0.73 51.7 ± 0.37 52.2 ± 0.35 52.9 ± 1.26 
50 56.6 ± 0.69 55 ± 0.59 54.2 ± 0.65 53.3 ± 1.16 
55 56.1 ± 0.50 57.8 ± 0.57 55.9 ± 0.87 53.4 ± 1.47 
60 57.5 ± 0.54 57.3 ± 0.26 57.8 ± 0.32 53.1± 0.47 
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TABLE - 8 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL 
USING PEG 6000 BY MELTING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 MM 1(1:1) MM 2(1:2) MM 3(1:3) MM 4(1:4) 
5 8.7 ± 0.32 10 ± 0.40 12 ± 0.34 12.4 ± 0.53 
10 15.3 ± 0.86 13.8 ± 0.65 14.8 ± 1.01 20.6 ± 0.61 
 19.7 ± 0.35 19.5 ± 0.34 18.6 ± 0.65 23.3 ± 0.53 
20 24.9 ± 0.65 21 ± 0.97     24.1 ± 0.65 31.7 ± 0.82 
25 30.9 ± 0.53 24.8 ± 1.01 30.1 ± 1.78 36.2 ± 0.82 
30 35.8 ± 0.61 30.9 ± 0.88 35.9 ± 0.65 37.9 ± 0.61 
35 40.9 ± 0.53 36.1 ± 0.65 40.4 ± 0.40 41.2 ± 1.43 
40 49.2 ± 0.53 43.2 ± 2.26 45 ± 1.02 45.1 ± 1.62 
45 54.1 ± 0.77 49 ± 0.91 49.2 ± 0.37 45.6 ± 0.82 
50 54.9 ± 0.49 54.1 ± 0.37 51.5 ± 0.65 46.5 ± 0.00 
55 54.9 ± 0.44 56.7 ± 0.34 54.7 ± 1.75 46.3 ± 0.04 
60 55.8 ± 0.54 59.7 ± 0.65 57.7 ± 1.08 46.6± 0.61 
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TABLE – 9 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL 
USING POLOXAMER 188 BY MELTING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
            
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 MM 5(1:1) MM 6(1:2) MM 7(1:3) MM 8(1:4) 
5 8.7 ±0.32 9.4 ±0.82 8.7 ±0.32 8.7 ±0.32 
10 16.9 ±0.30 13.4 ±0.80 16 ±2.60 11.6 ± 0.30 
15 21.9 ±0.53 15.1 ±0.61 21.8 ±0.61 15.9 ±0.49 
20 26.1 ±0.53 22 ±0.53 26.5 ±0.29 21.1 ±0.87 
25 31.6 ±0.53 27.3 ±0.32 31.4 ±0.68 25.5 ±0.49 
30 35.9 ±0.53 31.8 ±0.53 35.9 ±0.61 30.2 ±0.28 
35 41.8 ±0.32 36.8 ±0.00 38.9 ±0.57 33.4 ±0.57 
40 45.8 ±0.28 41.7 ±0.53 42.8 ±0.68 37.6 ±0.55 
45 50 ±0.82 45.7 ±0.32 44.2 ±0.77 40.5 ±1.72 
50 53.1 ±0.83 47.3 ±1.06 47.3 ±0.29 45.3 ±0.79 
55 54.4 ±1.65 50.4 ±0.94 49.3 ±0.65 47.7 ±0.78 
60 55.8 ±0.82 52.5 ±0.82 51.3 ±1.43 50.7 ±0.48 
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TABLE – 10 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL 
USING PVP K30 BY FREEZE DRYING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
  FD 1(1:1)    FD 2(1:2) FD 3(1:3) FD 4(1:4) 
5 19±1.06 21.2±1.11 22.3±1.63 19.4±0.77 
10 23.3±0.90 28.7±0.82 24.3±0.82 20.5±0.53 
15 38.1±1.35 36.9±1.27 26.5±0.30 23.8±1.11 
20 41.8±0.87 39.2±0.83 31.9±1.39 30.4±1.35 
25 45.6±1.31 43.8±0.87 35.3±1.06 39.5±1.69 
30 50.2±1.13 46.7±0.86 44.9±0.82 43.2±1.40 
35 50.5±1.88 50.1±0.82 50.4±1.14 46.6±1.97 
40 47.8±2.25 51.7±0.79 49.6±2.14 51.9±1.35 
45 48.3±0.82 46.9±1.71 49±0.09 54.6±1.76 
50 47±0.87 49.5±0.56 53.2±1.94 55.4±1.46 
55 45.7±0.53 51.7±1.46 57.4±0.88 56.9±0.87 
60 47.4±1.23 56±0.88 60.6±0.87 58.2±0.90 
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TABLE-11 CUMULATIVE % DRUG RELEASE PROFILE OF RACECADOTRIL 
USING PVP K30 BY SOLVENT EVAPORATION METHOD 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 SEM 1(1:1) SEM 2(1:2) SEM 3(1:3) SEM 4(1:4) 
5 10.2±1.66 6.1±4.34 10.5±1.06 6.3±4.48 
10 14.7±0.97 14.4±1.10 16.5±1.63 12.5±1.98 
15 21±2.35 23.3±1.11 23.4±0.68 18.1±1.61 
20 28.5±1.65 29.5±1.35 32.9±1.77 26.9±1.31 
25 40.6±2.17 39.5±0.57 36.9±1.58 31.5±1.02 
 30 41.3±1.06 54.4±0.92 44.2±0.77 36.7±1.40 
35 49.4±2.04 67.5±1.63 49±1.04 42±0.80 
40 52.6±3.15 77.2±0.82 54.2±0.40 46.3±1.32 
45 58.6±1.30 82.8±0.96 58±0.82 50.6±1.20 
50 63±0.75 58.1±0.92 61.1±1.96 52.1±2.33 
55 66.3±0.75 56.2±0.83 62.6±2.03 52.5±1.14 
60 69.4±1.62 54.2±1.35 63.2±2.34 51.3±1.10 
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                TABLE -12 CUMULATIVE % DRUG RELEASE PROFILE OF 
RACECADOTRIL USING PEG 6000 BY PHYSICAL MIXING METHOD 
 
 
 
 
 
 
                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 PM1(1:1) PM2(1:2) PM3(1:3) PM4(1:4) 
5 5.6 ± 4.90 5.9 ± 5.12 10.7 ± 1.60 17 ± 2.37 
10 9.4 ± 0.37 9.9 ± 0.70 11.4 ± 0.75 20.9 ± 1.06 
15 11 ± 0.46 13 ± 0.97 16.6 ± 2.37 22.9 ± 0.96 
20 14.9 ± 0.96 17.1 ± 1.06 21.4 ± 0.70 31.1 ± 2.02 
25 17.7 ± 0.43 19.7 ± 0.28 25.8 ± 0.72 41.7 ± 0.75 
30 19.2 ± 0.30 21.5 ± 0.46 36.8 ± 0.97 43.7 ± 0.96 
35 21.9 ± 0.66 24.3 ± 0.32 43.4 ± 3.99 44.4 ± 1.70 
40 24.3 ± 0.55 26.1 ± 0.65 46.9 ± 0.98 39.1 ± 1.79 
45 25.9 ± 0.51 27.5 ± 0.37 46.1 ± 1.28 40.9 ± 0.70 
50 27.9 ± 0.61 28± 0.65 43.5 ± 2.84 41.3 ± 0.60 
55 29.4 ± 0.36 29.4 ± 0.92 42.2 ± 0.97 44.4 ± 0.60 
60 31.5 ± 0.26 30.6 ± 0.60 42.4 ± 0.65 45.9± 1.30 
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                   TABLE - 13 CUMULATIVE % DRUG RELEASE PROFILE OF 
RACECADOTRIL USING PVP K30 BY PHYSICAL MIXING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 PM5(1:1) PM6(1:2) PM7(1:3) PM8(1:4) 
5 10.9 ± 1.60 2.8 ± 4.90 12.4 ± 0.65 2.8 ± 4.00 
10 16.3 ± 1.34 12 ± 1.36 16.7 ± 1.50 9.4 ± 0.32 
15 17.7 ± 1.36 15.9 ± 1.35 21.9 ± 2.37 12.3 ± 0.78 
20 19.7 ± 0.80 19.5 ± 1.65 24.4 ± 0.32 17.3 ± 0.53 
25 28.7 ± 1.50 24.8 ± 0.70 30.1 ± 1.53 22.3 ± 0.32 
30 31.4 ± 2.35 27 ± 0.65 30.2 ± 2.25 26.3 ± 0.53 
35 35.7 ± 0.97 29.7 ± 1.97 32.3 ± 1.70 29.4 ± 0.32 
40 38.3 ± 1.55 33.8 ± 2.04 37 ± 0.32 32.3 ± 0.30 
45 40.4 ± 1.30 37.7 ± 0.43 39.6 ± 1.09 35.3 ± 0.78 
50 40.6 ± 3.69 38.9± 1.81 41.1 ± 0.80 36.8 ± 0.53 
55 42.4 ± 1.35 38.1± 1.35 40.4 ± 0.05 37.2 ± 0.53 
60 43.1 ± 1.65 38.7± 0.43 40 ± 0.96 37.5± 0.97 
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       TABLE- 14 CUMULATIVE % DRUG RELEASE PROFILE OF 
RACECADOTRIL USING POLOXAMER 188 BY PHYSICAL MIXING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
CUMULATIVE % DRUG RELEASE±SD* 
 PM9(1:1) PM 10(1:2) PM 11(1:3) PM 12(1:4) 
5 5.9 ± 4.18 8.9 ± 0.61 9.4 ± 0.82 11.3 ± 0.79 
10 13.3 ± 0.86 14.7 ± 0.79 15.8 ± 0.53 16.3 ± 0.28 
15 18.3 ± 0.26 20.8 ± 0.32 21.7 ± 1.44 20.6 ± 0.53 
20 21.6 ± 0.79 23.5 ± 1.06 25.6 ± 0.83 24.3 ± 0.30 
25 24.7 ± 0.30 26.8 ± 0.28 32.5 ± 0.87 28.8 ± 0.30 
30 29.1 ± 0.57 30.8 ± 0.32 36.4 ± 0.28 32.6 ± 0.53 
35 33 ± 0.35 36.2 ± 0.57 40.9 ± 1.10 36.9 ± 1.10 
40 37 ± 0.61 40.7 ± 0.83 45.1 ± 0.30 43.7 ± 0.35 
45 42.9 ± 0.78 43.5 ± 0.53 48 ± 0.26 47.6 ± 0.53 
50 44.2 ± 0.26   46.7 ± 0.57 50.3 ± 0.57 47.9 ± 0.26 
55 46 ± 0.30 50 ± 0.28 50.8 ± 0.48 49.8 ± 1.27 
60 47.8 ± 0.30 52.3 ± 0.57 52.2 ± 0.29 51.1± 0.57 
                                                                                                                                              TABLES 
 
SOLID DISPERSION Page 91 
 
 
 
 
 
          TABLE - 15   COMPARISION OF SOLUBILITY STUDY OF RACECADOTRIL 
USING DISTILLED WATER AND ACID BUFFER pH 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
 
FORMULATION 
 
 
DISTILLED WATER 
(mg/ml) 
 
ACID 
BUFFER 
pH 1.2 
(mg/ml) 
1  
PURE DRUG 
 
0.076 
 
0.103 
2 PHYSICAL MIXTURE 
(Drug:PVP K30 1:3) 
 
0.110 
 
0.161 
3 SOLID DISPERSION 
(KM 7) 
 
0.160 
 
0.344 
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 TABLE - 16 COMPARISIONOF IN-VITRO RELEASE PROFILE OF BEST               
FORMULATION (KM7) WITH MARKETED FORMULATION 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIME IN 
MINUTES 
      CUMULATIVE % DRUG RELEASE±SD* 
 PURE DRUG KM 7 (1:3) 
MARKETED 
CAPSULE 
5 5.6±4.90 9.6 ± 0.61 19.2 ± 1.66 
10 9.4±0.37 13.4 ± 0.82 22.1 ± 0.46 
15 11.5±1.06 18.4 ± 0.63 23.7 ± 0.81 
20 12.9±1.02 23 ± 0.82 26.8 ± 2.20 
25 15.3±0.98 48.8 ± 1.74 30.6 ± 0.66 
30 18.5±0.32 53.6± 0.53 34.6 ± 0.73 
35 22.5±0.60 56.3 ± 0.53 36.8 ± 0.94 
40 24.9±0.43 60.4± 0.83 39 ± 1.02 
45 25.6±0.70 64.4 ± 0.83 41.5 ± 1.05 
50 26.1±0.43 67.3 ± 0.35 43.5 ± 0.79 
55 27.4±0.05 70 ± 0.63 44.2 ± 0.10 
60 28.1±0.32 72.7 ± 0.35 44.8 ± 0.87 
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FIGURE 1-A      DETERMINATION OF λ max OF RACECADOTRIL 
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Figure- 1-B   CALIBRATION OF RACECADOTRIL (pH 1.2) 
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Figure- 2 IN-VITRO RELEASE PROFILE OF RACECADOTRIL (PURE DRUG) 
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Figure-3   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING PEG6000                                                     
BY KNEADING METHOD 
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Figure-4   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING PVP K30                                                     
BY KNEADING METHOD 
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Figure-5   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING POLOXAMER 188                                
BY KNEADING METHOD 
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Figure-6   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING PEG6000                                                     
BY MELTING METHOD 
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Figure-7   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING POLOXAMER 188                                   
BY MELTING METHOD 
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Figure-8   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING POLOXAMER 188                           
(PHYSICAL MIXTURE) 
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Figure-9   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING PEG 6000                                   
(PHYSICAL MIXTURE) 
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Figure-10   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING PVP K30                                 
(PHYSICAL MIXTURE) 
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Figure-11   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND PHYSICAL MIXTURE USING PEG 6000(1:1) 
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Figure-12   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND PHYSICAL MIXTURE USING PEG 6000(1:2) 
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Figure-13   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING PEG 6000(1:3) 
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Figure-14   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND PHYSICAL MIXTURE USING PEG 6000(1:4) 
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Figure-15   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING POLOXAMER 188 (1:1) 
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Figure-16   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND PHYSICAL MIXTURE USING POLOXAMER 188 (1:2) 
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Figure-17   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING POLOXAMER 188 (1:3) 
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Figure-18   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING POLOXAMER 188 (1:4) 
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Figure-19   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING PVP K30 (1:1 
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Figure-22   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING PVP K30 (1:4) 
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Figure-21   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING PVP K30 (1:3) 
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Figure-20   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL PURE DRUG WITH SILID DISPERSION 
AND  PHYSICAL MIXTURE USING PVP K30 (1:2) 
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Figure-23   COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL USING PVP K30                                                    
BY FREEZE DRYING MEYHOD 
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Figure-24 COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL  USING PVP K30                                                    
BY SOLVENT EVAPORATION MEYHOD 
 
                                                                                                                                                                                                         FIGURES 
 
SOLID DISPERSION Page 118 
 
 TIME IN MINS
C
U
M
U
L
A
T
I
V
E
 
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 10 20 30 40 50 60
0
10
20
30
40
50
60
70
80
90
100
BEST FORMULATION(KM 7)
MARKETED FORMULATION
 
Figure-25  COMPARISON OF IN-VITRO RELEASE PROFILE OF RACECADOTRIL MARKETED CAPSULES WITH BEST 
FORMULATION (KM 7) 
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Figure-26  COMPARISON OF SOLUBILITY STUDY OF RACECADOTRIL USING DISTILLED WATER                                           
AND ACID BUFFER pH1.2 
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FT-IR  STUDIES 
 
FTIR SPECTRUM
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                                                   FIG -27   FTIR SPECTRUM OF RACECADOTRIL 
 
 
FTIR SPECTRUM
Spectrum Name: PEG 6000.sp 
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    FIG – 28   FTIR SPECTRUM OF PEG 6000 
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FTIR SPECTRUM
Spectrum Name: Poloxamer 188.sp 
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                                      FIG - 29   FTIR SPECTRUM OF POLOXAMER 188 
 
 
FTIR SPECTRUM
Spectrum Name: PVP K30.sp 
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FIG - 30    FTIR SPECTRUM OF PVP K30                                 
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FTIR SPECTRUM
Spectrum Name: RACECADOTRIL PEG6000.sp 
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                     FIG -31 FTIR SPECTRUMS OF RACECADOTRIL+PEG 6000 
 
FTIR SPECTRUM
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                       FIG -32 FTIR SPECTRUM OF RACECADOTRIL+POLOXAMER 188 
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FTIR SPECTRUM
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                      FIG -33 FTIR SPECTRUM OF RACECADOTRIL+PVP K30 
 
 
DSC STUDIES 
 
                                      FIG - 34 DSC THERMOGRAM OF RACECADOTRIL 
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                                   FIG - 35 DSC THERMOGRAM OF PEG6000 
 
 
 
                                    FIG – 36 DSC THERMOGRAM OF POLOXAMER 188 
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                                        FIG – 37  DSC THERMOGRAM OF PVP 30 
 
 
                                       FIG – 38 DSC THERMOGRAM OF DRUG+PEG6000 
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                             FIG – 39  DSC THERMOGRAM OF  DRUG+POLOXAMER 188 
 
 
 
                           FIG – 40 DSC THERMOGRAM OF DRUG+PVP K30 
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POWDER X-RAY DIFFRACTION STUDIES 
 
FIG - 41  PURE DRUG (Racecadotril) 
 
FIG - 42 PHYSICAL MIXTURE (PM 7) 
              
 
FIG - 43 RACECADOTRIL SOLID DISPERSION (KM7) 
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                                                    CHAPTER- XI 
                                      SUMMARY AND CONCLUSION 
 The purpose of this study was to prepare solid dispersions of Racecadotril to 
improve the solubility and dissolution rate. 
 Kneading method, Melting Method, Solvent Evaporation Method and freeze 
drying methods were employed to prepare solid dispersions. 
 The formulated solid dispersions were characterized for in vitro release studies 
in Hydrochloric acid buffer pH1.2, using USP Type I apparatus. 
 The solid dispersion systems of Racecadotril prepared with the water soluble 
carriers PEG 6000, Poloxamer 188 and PVP K30 show better in vitro release. 
 The results revealed that the increase in the carrier concentration, decreases the 
dissolution rate(1:4 ratios). Faster dissolution rate was observed in the order of PVP 
K30 > Poloxamer 188 > PEG 6000. 
 The in vitro release studies revealed that the solid dispersion formulations 
showed a faster drug release compared to the physical mixture and pure drug. 
 FT-IR studies showed that there is no interaction between the drug Racecadotril 
and the carriers. 
 The results of the Powder X-ray diffraction (PXRD) studies proved that 
crystallinity of the drug Racecadotril was remarkably reduced the best formulation 
(KM7). 
 Crystallinity of the drug was reduced in the solid dispersion prepared by using    
PVP K30 in the ratio 1:3 with kneading method. 
 The solubility studies was observed that the solid dispersion(KM7) have highest 
solubility compared to pure drug and physical mixture in distilled water and acid buffer 
pH 1.2.  
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 The DSC thermograms of Racecadotril and of its physical mixtures, the sharp 
melting point peak of pure racecadotril appeared at 80.9
0
C, whereas no such peak was 
observed in physical mixtures (1:1) prepared with PEG6000, PVP K30 and Poloxamer 
188, suggesting that Racecadotril was molecularly dispersed and in an amorphous form. 
 
 CONCLUSION: 
It is concluded that the kneading,  melting, solvent evaporation and freeze 
drying methods  are useful methods for the successful enhancement of solubility of 
poorly water soluble drug Racecadotril with faster dissolution rate.  Further, it may be 
assumed that the solubility and dissolution rate can be increased due to the conversion 
of crystalline matter into amorphous powder. Hence we can conclude that solid 
dispersion of Racecadotri by using the water soluble carrier PVP K30 in the ratio 1:3 
prepared by kneading method provide best release of drug (72.7% released in 60 mins) 
among all the formulations, and this ratio can be used to enhance the solubility and 
dissolution rate of poorly water soluble drug Racecadotril. 
. 
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